pragmeta_trial_id,doi,domain_name,quote,best_match,ratio
1494,10.1056/nejmoa1805101,Eligibility,"We performed a multicenter, open-label, randomized, controlled trial involving patients 18 to 75 years of age with resectable cancer of the middle or lower third of the esophagus.","We performed a multicenter, open-label, randomized, controlled trial involving patients 18 to 75 years of age with resectable cancer of the middle or lower third of the esophagus.",100.0
1494,10.1056/nejmoa1805101,Eligibility,"Specific inclusion criteria were the following: squamous-cell carcinoma or adenocarcinoma of thoracic esophagus with a clinical stage of I, II, or III (tumor stage 1 through 3 [T1, T2, or T3], no nodal involvement [N0] or presence of cancer in lymph nodes [N1] or in distant lymph nodes [≥5 cm from the tumor; N2], and no metastases [M0]) before the receipt of any induction treatment; esophageal cancer in the middle or lower third of the esophagus or junctional (Siewert’s type I) tumor; the receipt or nonreceipt of neoadjuvant radiotherapy, chemotherapy, or both; tumors that were considered to be resectable with a curative intention at the time of preoperative evaluation; an age of 18 to 75 years; a World Health Organization performance-status score of 0, 1, or 2 (on a 5-point scale, with higher numbers indicating greater disability); ability to provide written informed consent; ability to undergo one of the investigated surgical procedures; and ability to attend the follow-up visits.","Specific inclusion criteria were the following: squamous-cell carcinoma or adenocarcinoma of thoracic esophagus with a clinical stage of I, II, or III (tumor stage 1 through 3 [T1, T2, or T3], no nodal involvement [N0] or presence of cancer in lymph nodes [N1] or in distant lymph nodes [≥5 cm from the tumor; N2], and no metastases [M0]) before the receipt of any induction treatment; esophageal cancer in the middle or lower third of the esophagus or junctional (Siewert’s type I) tumor; the receipt or nonreceipt of neoadjuvant radiotherapy, chemotherapy, or both; tumors that were considered to be resectable with a curative intention at the time of preoperative evaluation; an age of 18 to 75 years; a World Health Organization performance-status score of 0, 1, or 2 (on a 5-point scale, with higher numbers indicating greater disability); ability to provide written informed consent; ability to undergo one of the investigated surgical procedures; and ability to attend the follow-up visits.",100.0
1494,10.1056/nejmoa1805101,Recruitment,The trial was conducted at 13 centers in France.,The trial was conducted at 13 centers in France,100.0
1494,10.1056/nejmoa1805101,Setting,The trial was conducted at 13 centers in France.,The trial was conducted at 13 centers in France,100.0
1494,10.1056/nejmoa1805101,Organisation,"All the participating centers had surgeons who were experienced in esophageal-cancer surgery and in laparoscopic gastric mobilization, with at least 25 procedures performed at each center before it was included in the trial.","All the participating centers had surgeons who were experienced in esophageal-cancer surgery and in laparoscopic gastric mobilization, with at least 25 procedures performed at each center before it was included in the trial.",100.0
1494,10.1056/nejmoa1805101,Flexibility (delivery),"Despite the difference in approach to the abdominal component of the surgical procedure, the surgical technique was standardized between groups and performed as described previously.","Despite the difference in approach to the abdominal component of the surgical procedure, the surgical technique was standardized between groups and performed as described previously.",100.0
1494,10.1056/nejmoa1805101,Follow-up,Patients were followed up at 30 days after surgery and every 6 months for 3 years after surgery.,Patients were followed up at 30 days after surgery and every 6 months for 3 years after surgery.,100.0
1494,10.1056/nejmoa1805101,Primary outcome,The primary end point was major complication during surgery or within 30 days after surgery.,The primary end point was major complication during surgery or within 30 days after surgery.,100.0
1494,10.1056/nejmoa1805101,Primary analysis,"All the analyses were performed on an intention-to-treat basis; the analyses included all the patients who had undergone randomization, regardless of the surgery performed and eligibility criteria.","All the analyses were performed on an intention-to-treat basis; the analyses included all the patients who had undergone randomization, regardless of the surgery performed and eligibility criteria.",100.0
673,10.1177/1352458512461966,Eligibility,"Participants were randomised in groups of eight to physiotherapist (PT)-led exercise (n = 80), yoga (n = 77), fitness instructor (FI)-led exercise (n = 86) and they took part in weekly community-based group exercise sessions.","Participants were randomised in groups of eight to physiotherapist (PT)-led exercise (n = 80), yoga (n = 77), fitness instructor (FI)-led exercise (n = 86) and they took part in weekly community-based group exercise sessions.",100.0
673,10.1177/1352458512461966,Eligibility,"Our study participants were referred to the project by themselves, their care-giver, MSI, chartered physiotherapists, neurologists, general practitioners or clinical nurse specialists.","Our study participants were referred to the project by themselves, their care-giver, MSI, chartered physiotherapists, neurologists, general practitioners or clinical nurse specialists.",100.0
673,10.1177/1352458512461966,Eligibility,Eligible participants were over 18 years of age and had a diagnosis of MS that was confirmed by a consultant physician or neurologist.,Eligible participants were over 18 years of age and had a diagnosis of MS that was confirmed by a consultant physician or neurologist.,100.0
673,10.1177/1352458512461966,Recruitment,"Participants were randomised in groups of eight to physiotherapist (PT)-led exercise (n = 80), yoga (n = 77), fitness instructor (FI)-led exercise (n = 86) and they took part in weekly community-based group exercise sessions.","Participants were randomised in groups of eight to physiotherapist (PT)-led exercise (n = 80), yoga (n = 77), fitness instructor (FI)-led exercise (n = 86) and they took part in weekly community-based group exercise sessions.",100.0
673,10.1177/1352458512461966,Recruitment,"Our study participants were referred to the project by themselves, their care-giver, MSI, chartered physiotherapists, neurologists, general practitioners or clinical nurse specialists.","Our study participants were referred to the project by themselves, their care-giver, MSI, chartered physiotherapists, neurologists, general practitioners or clinical nurse specialists.",100.0
673,10.1177/1352458512461966,Setting,"All interventions took place in groups of eight, for an hour per week, for 10 weeks.","All interventions took place in groups of eight, for an hour per week, for 10 weeks.",100.0
673,10.1177/1352458512461966,Setting,"They were delivered in community centres such as local gyms, hotels and health centres.","They were delivered in community centres such as local gyms, hotels and health centres.",100.0
673,10.1177/1352458512461966,Organisation,The PT-led exercise provided was pre-defined.,The PT-led exercise provided was pre-defined.,100.0
673,10.1177/1352458512461966,Organisation,"The FI-led classes were not pre-defined, as the aim was to establish whether these classes were effective when encountered by those with MS in the community.","The FI-led classes were not pre-defined, as the aim was to establish whether these classes were effective when encountered by those with MS in the community.",100.0
673,10.1177/1352458512461966,Organisation,The yoga intervention was also not predefined.,The yoga intervention was also not predefined,100.0
673,10.1177/1352458512461966,Flexibility (delivery),The PT-led exercise provided was pre-defined.,The PT-led exercise provided was pre-defined.,100.0
673,10.1177/1352458512461966,Flexibility (delivery),"The FI-led classes were not pre-defined, as the aim was to establish whether these classes were effective when encountered by those with MS in the community.","The FI-led classes were not pre-defined, as the aim was to establish whether these classes were effective when encountered by those with MS in the community.",100.0
673,10.1177/1352458512461966,Flexibility (delivery),The yoga intervention was also not predefined.,The yoga intervention was also not predefined,100.0
673,10.1177/1352458512461966,Flexibility (adherence),"All interventions took place in groups of eight, for an hour per week, for 10 weeks.","All interventions took place in groups of eight, for an hour per week, for 10 weeks.",100.0
673,10.1177/1352458512461966,Flexibility (adherence),Treatment fidelity was optimized by the instructors and participants documenting program adherence.,Treatment fidelity was optimised by the instructors and participants documenting programme adheren,96.93877551020408
673,10.1177/1352458512461966,Follow-up,"Outcome was assessed at week 24 for the intervention groups only, as it was felt that withholding a potentially beneficial treatment for longer than 12 weeks, from the controls, could be considered unethical.","Outcome was assessed at week 24 for the intervention groups only, as it was felt that withholding a potentially beneficial treatment for longer than 12 weeks, from the controls, could be considered unethical.",100.0
673,10.1177/1352458512461966,Primary outcome,"The primary outcome was the Multiple Sclerosis Impact Scale (MSIS) 29v2 physical component, measured before and after the 10-week intervention.","The primary outcome was the Multiple Sclerosis Impact Scale (MSIS) 29v2 physical component, measured before and after the 10-week intervention.",100.0
673,10.1177/1352458512461966,Primary analysis,All participants were analyzed in the groups to which they were randomized.,All participants were analysed in the groups to which they were randomised,97.2972972972973
1330,10.1097/sla.0000000000000982,Eligibility,"The inclusion criterion was planned unilateral adrenal surgery for a benign tumor up to 7 cm in diameter. Exclusion criteria were diffuse peritonitis in history, major abdominal surgery in history, planned bilateral adrenal surgery, adrenal tumor more than 7 cm in diameter, suspected adrenocortical cancer, metastasis to adrenal gland, previous adrenal surgery, pregnancy or lactation, age less than 18 or more than 80 years, American Society of Anesthesiologists fitness grade IV, and inability to comply with the follow-up protocol.","The inclusion criterion was planned unilateral adrenal surgery for a benign tumor up to 7 cm in diameter. Exclusion criteria were diffuse peritonitis in history, major abdominal surgery in history, planned bilateral adrenal surgery, adrenal tumor more than 7 cm in diameter, suspected adrenocortical cancer, metastasis to adrenal gland, previous adrenal surgery, pregnancy or lactation, age less than 18 or more than 80 years, American Society of Anesthesiologists fitness grade IV, and inability to comply with the follow-up protocol.",100.0
1330,10.1097/sla.0000000000000982,Eligibility,The patients were randomized to one of the parallel groups: PRA or LTLA.,The patients were randomized to one of the parallel groups: PRA or LTLA.,100.0
1330,10.1097/sla.0000000000000982,Recruitment,"Eighty-eight patients were referred for adrenal surgery and were potential candidates for the study. Twenty patients did not meet the inclusion criteria and 3 refused to participate, leaving 65 patients with complete short-term follow-up (33 in the PRA and 32 in the LTLA group) and 61 patients who were followed-up for 5 years (30 in the PRA and 31 in the LTLA group) as shown in Fig. 1.","Eighty-eight patients were referred for adrenal surgery and were potential candidates for the study. Twenty patients did not meet the inclusion criteria and 3 refused to participate, leaving 65 patients with complete short-term follow-up (33 in the PRA and 32 in the LTLA group) and 61 patients who were followed-up for 5 years (30 in the PRA and 31 in the LTLA group) as shown in Fig. 1.",100.0
1330,10.1097/sla.0000000000000982,Setting,"Patients referred to the Third Department of General Surgery, Jagiellonian University Medical College, Krakow, between January 2006 and June 2008 for first time adrenal surgery were registered.","Patients referred to the Third Department of General Surgery, Jagiellonian University Medical College, Krakow, between January 2006 and June 2008 for first time adrenal surgery were registered.",100.0
1330,10.1097/sla.0000000000000982,Organisation,All operations in this study were unilateral total adrenalectomies and were carried out by a single experienced endocrine surgeon (M.B.) under general anesthesia.,All operations in this study were unilateral total adrenalectomies and were carried out by a single experienced endocrine surgeon (M.B.) under general anesthesia.,100.0
1330,10.1097/sla.0000000000000982,Organisation,"The surgeon (M.B.) completed a training program in LTLA during his visiting observership in 2002 in the Mount Sinai School of Medicine, Minimally Invasive Surgery Center (New York) headed by M. Gagner, and in PRA during his visiting observership in 2003 in the Department of Surgery and Center for Minimally Invasive Surgery, University of Essen (Essen, Germany) headed by M. Walz.","The surgeon (M.B.) completed a training program in LTLA during his visiting observership in 2002 in the Mount Sinai School of Medicine, Minimally Invasive Surgery Center (New York) headed by M. Gagner, and in PRA during his visiting observership in 2003 in the Department of Surgery and Center for Minimally Invasive Surgery, University of Essen (Essen, Germany) headed by M. Walz.",100.0
1330,10.1097/sla.0000000000000982,Flexibility (delivery),All operations in this study were unilateral total adrenalectomies and were carried out by a single experienced endocrine surgeon (M.B.) under general anesthesia.,All operations in this study were unilateral total adrenalectomies and were carried out by a single experienced endocrine surgeon (M.B.) under general anesthesia.,100.0
1330,10.1097/sla.0000000000000982,Flexibility (delivery),The same anesthesia protocol was used in all the patients.,The same anesthesia protocol was used in all the patients.,100.0
1330,10.1097/sla.0000000000000982,Flexibility (adherence),The patients were encouraged to be mobilized and to drink and eat soon after returning from the recovery room.,The patients were encouraged to be mobilized and to drink and eat soon after returning from the recovery room.,100.0
1330,10.1097/sla.0000000000000982,Follow-up,The patients were encouraged to be mobilized and to drink and eat soon after returning from the recovery room.,The patients were encouraged to be mobilized and to drink and eat soon after returning from the recovery room.,100.0
1330,10.1097/sla.0000000000000982,Follow-up,"The prevalence of postoperative complications was evaluated during hospitalization and visits at the outpatient surgical department scheduled at 7 days and 1, 12, 24, 36, 48, and 60 months after the operation.","The prevalence of postoperative complications was evaluated during hospitalization and visits at the outpatient surgical department scheduled at 7 days and 1, 12, 24, 36, 48, and 60 months after the operation.",100.0
1330,10.1097/sla.0000000000000982,Primary outcome,The primary endpoint was duration of surgery.,The primary endpoint was duration of surgery.,100.0
1330,10.1097/sla.0000000000000982,Primary analysis,Data are presented as mean with 95% confidence interval (CI) unless stated otherwise. The analysis of primary and secondary variables was performed on an intention-to-treat basis.,Data are presented as mean with 95% confidence interval (CI) unless stated otherwise. The analysis of primary and secondary variables was performed on an intention-to-treat basis.,100.0
1299,10.1097/sla.0000000000002892,Eligibility,"The inclusion criteria were a BMI between 35 and 60 kg/m2, age between 18 and 60 years, and primary SG. The exclusion criteria were history of bariatric or gastric surgery, a surgical procedure other than primary SG, a BMI ≥60 kg/m2, age under 18, allergy or contraindication to TISSEEL, legal guardianship, refusal to participate in the study, pregnancy or breastfeeding, and an American Society of Anesthesiologists score of IV.","The inclusion criteria were a BMI between 35 and 60 kg/m2, age between 18 and 60 years, and primary SG. The exclusion criteria were history of bariatric or gastric surgery, a surgical procedure other than primary SG, a BMI ≥60 kg/m2, age under 18, allergy or contraindication to TISSEEL, legal guardianship, refusal to participate in the study, pregnancy or breastfeeding, and an American Society of Anesthesiologists score of IV.",100.0
1299,10.1097/sla.0000000000002892,Eligibility,Patients with a positive intraoperative methylene blue test and/or abdominal drainage and/or intraoperative bleeding requiring staple line suturing were not excluded.,Patients with a positive intraoperative methylene blue test and/or abdominal drainage and/or intraoperative bleeding requiring staple line suturing were not excluded.,100.0
1299,10.1097/sla.0000000000002892,Recruitment,"During a consultation before bariatric surgery, patients meeting the study's inclusion criteria were invited to participate in the study and were also provided with an information sheet on the study objectives and procedures.","During a consultation before bariatric surgery, patients meeting the study's inclusion criteria were invited to participate in the study and were also provided with an information sheet on the study objectives and procedures.",100.0
1299,10.1097/sla.0000000000002892,Setting,"This was a prospective, intention-to-treat, randomized, single-blind, 2-center superiority study of a group of patients (n = 586) undergoing primary SG between February 2014 and June 2017.","This was a prospective, intention-to-treat, randomized, single-blind, 2-center superiority study of a group of patients (n = 586) undergoing primary SG between February 2014 and June 2017.",100.0
1299,10.1097/sla.0000000000002892,Organisation,"The present study was sponsored and funded by the FS's manufacturer (Baxter International Inc.). The sponsor was not involved in the study design, data collection, statistical analysis, or formulation of the results.","The present study was sponsored and funded by the FS's manufacturer (Baxter International Inc.). The sponsor was not involved in the study design, data collection, statistical analysis, or formulation of the results.",100.0
1299,10.1097/sla.0000000000002892,Flexibility (delivery),"The 4-trocar SG technique has been described in detail by Dhahri et al.20 A 34 Fr bougie guided the stapling, and stapling was started 6 cm proximal to the pylorus using a Endo Gia Ultra Universal XL Stapler 60 with Tri-staple purple reloads (Covidien France SAS, Elancourt, France) or an Echelon Flex Endopath 60-mm stapler with green reloads (Ethicon Endo-Surgery, Issy-les-Moulineaux, France). No buttress material or GSL over sewing was used.","The 4-trocar SG technique has been described in detail by Dhahri et al.20 A 34 Fr bougie guided the stapling, and stapling was started 6 cm proximal to the pylorus using a Endo Gia Ultra Universal XL Stapler 60 with Tri-staple purple reloads (Covidien France SAS, Elancourt, France) or an Echelon Flex Endopath 60-mm stapler with green reloads (Ethicon Endo-Surgery, Issy-les-Moulineaux, France). No buttress material or GSL over sewing was used.",100.0
1299,10.1097/sla.0000000000002892,Follow-up,"The trial's primary endpoint was a composite of the SLCs recorded over the first 30 PODs. Surgical complications were defined as GL, postoperative hemorrhage/hematoma at the GSL and postoperative abscess near to the GSL. The occurrence of a postoperative complication was assessed by an independent adjudication committee composed of physicians not involved in the recruitment and the management of patients undergoing SG.","The trial's primary endpoint was a composite of the SLCs recorded over the first 30 PODs. Surgical complications were defined as GL, postoperative hemorrhage/hematoma at the GSL and postoperative abscess near to the GSL. The occurrence of a postoperative complication was assessed by an independent adjudication committee composed of physicians not involved in the recruitment and the management of patients undergoing SG.",100.0
1299,10.1097/sla.0000000000002892,Primary outcome,The primary endpoint (composite criteria) was the incidence of SLCs in each of the 2 groups.,The primary endpoint (composite criteria) was the incidence of SLCs in each of the 2 groups.,100.0
1299,10.1097/sla.0000000000002892,Primary analysis,"In the intention-to-treat analysis, the incidence of SLCs was similar in the FS and control groups (1.3% vs 2%, respectively; P = 0.52).","In an intention-to-treat analysis, the incidence of SLCs was similar in the FS and control groups (1.3% vs 2%, respectively; P = 0.52)",97.76119402985076
1656,10.1056/nejmoa1303006,Eligibility,"From July 2007 through December 2010, we enrolled 353 participants 18 years of age or older who met 1987 American College of Rheumatology (ACR) classification criteria for rheumatoid arthritis,26 had been receiving methotrexate at stable doses of 15 to 25 mg weekly for at least 12 weeks, had a DAS28 of 4.4 or higher, and met inclusion criteria and had no exclusion criteria.","From July 2007 through December 2010, we enrolled 353 participants 18 years of age or older who met 1987 American College of Rheumatology (ACR) classification criteria for rheumatoid arthritis,26 had been receiving methotrexate at stable doses of 15 to 25 mg weekly for at least 12 weeks, had a DAS28 of 4.4 or higher, and met inclusion criteria and had no exclusion criteria",100.0
1656,10.1056/nejmoa1303006,Eligibility,"Our study has several limitations. First, the target sample size was not reached. Despite this shortfall, the 95% confidence interval for noninferiority did not approach the conservatively defined threshold of 0.6. Since a DAS28 change of 1.2 or more is an accepted standard for clinically meaningful change,29 a DAS28 change of 0.6 or less was thought to be clinically insignificant.","Our study has several limitations. First, the target sample size was not reached. Despite this shortfall, the 95% confidence interval for noninferiority did not approach the conservatively defined threshold of 0.6. Since a DAS28 change of 1.2 or more is an accepted standard for clinically meaningful change,29 a DAS28 change of 0.6 or less was thought to be clinically insignificant.",100.0
1656,10.1056/nejmoa1303006,Recruitment,"From July 2007 through December 2010, we enrolled 353 participants 18 years of age or older who met 1987 American College of Rheumatology (ACR) classification criteria for rheumatoid arthritis,26 had been receiving methotrexate at stable doses of 15 to 25 mg weekly for at least 12 weeks, had a DAS28 of 4.4 or higher, and met inclusion criteria and had no exclusion criteria.","From July 2007 through December 2010, we enrolled 353 participants 18 years of age or older who met 1987 American College of Rheumatology (ACR) classification criteria for rheumatoid arthritis,26 had been receiving methotrexate at stable doses of 15 to 25 mg weekly for at least 12 weeks, had a DAS28 of 4.4 or higher, and met inclusion criteria and had no exclusion criteria",100.0
1656,10.1056/nejmoa1303006,Setting,"The trial was conducted at 16 Veteran Affairs hospitals, 12 Rheumatoid Arthritis Investigational Network sites, and 8 Canadian medical centers.","The trial was conducted at 16 Veteran Affairs hospitals, 12 Rheumatoid Arthritis Investigational Network sites, and 8 Canadian medical centers.",100.0
1656,10.1056/nejmoa1303006,Organisation,"The Veterans Affairs Cooperative Studies Program was responsible for the collection of the data, the analysis of the data (Boston site), the provision of and payment for study medications, and the preparation and distribution of the placebo (Albuquerque site). Amgen donated the placebo etanercept but had no role in the design of the study, the collection or analysis of the data, the writing of the manuscript, or the decision to submit the manuscript for publication.","The Veterans Affairs Cooperative Studies Program was responsible for the collection of the data, the analysis of the data (Boston site), the provision of and payment for study medications, and the preparation and distribution of the placebo (Albuquerque site). Amgen donated the placebo etanercept but had no role in the design of the study, the collection or analysis of the data, the writing of the manuscript, or the decision to submit the manuscript for publication.",100.0
1656,10.1056/nejmoa1303006,Flexibility (delivery),"Participants continued to receive methotrexate throughout the trial, at the dose that they were receiving at the time of enrollment.","Participants continued to receive methotrexate throughout the trial, at the dose that they were receiving at the time of enrollment.",100.0
1656,10.1056/nejmoa1303006,Flexibility (adherence),Adherence to study medications was assessed by means of tablet counts in returned bottles and with the use of diaries in which participants noted injection dates.,Adherence to study medications was assessed by means of tablet counts in returned bottles and with the use of diaries in which participants noted injection dates.,100.0
1656,10.1056/nejmoa1303006,Follow-up,"Participants were seen every 6 weeks for monitoring of laboratory values and adverse events. At the time of enrollment and every 12 weeks, the Health Assessment Questionnaire II27 was administered, a count of joints with disease activity was performed, and pain was assessed. At the time of enrollment and every 24 weeks, the DAS28 was calculated, the physician's global assessment (an overall assessment of disease) was performed, quality-of-life and functional surveys were administered, and radiographs were obtained.","Participants were seen every 6 weeks for monitoring of laboratory values and adverse events. At the time of enrollment and every 12 weeks, the Health Assessment Questionnaire II27 was administered, a count of joints with disease activity was performed, and pain was assessed. At the time of enrollment and every 24 weeks, the DAS28 was calculated, the physician's global assessment (an overall assessment of disease) was performed, quality-of-life and functional surveys were administered, and radiographs were obtained.",100.0
1656,10.1056/nejmoa1303006,Primary outcome,The primary outcome was the change in the DAS28 at 48 weeks according to the initial regimen.,The primary outcome was the change in the DAS28 at 48 weeks according to the initial regimen.,100.0
1656,10.1056/nejmoa1303006,Primary analysis,"We tested the one-sided hypothesis that triple therapy would not be inferior to etanercept–methotrexate therapy, with rejection of the null hypothesis if the upper limit of a one-sided 95% confidence interval for the difference between the groups in the change from baseline to 48 weeks (triple therapy minus etanercept–methotrexate therapy) would be less than 0.6.","We tested the one-sided hypothesis that triple therapy would not be inferior to etanercept–methotrexate therapy, with rejection of the null hypothesis if the upper limit of a one-sided 95% confidence interval for the difference between the groups in the change from baseline to 48 weeks (triple therapy minus etanercept–methotrexate therapy) would be less than 0.6.",100.0
1465,10.1016/j.athoracsur.2018.05.023,Eligibility,"Patients with isolated palmar, isolated axillary, and isolated or associated plantar hyperhidrosis were excluded from this study.","Patients with isolated palmar, isolated axillary, and isolated or associated plantar hyperhidrosis were excluded from this study.",100.0
1465,10.1016/j.athoracsur.2018.05.023,Eligibility,Family history was positive in 33 patients (55%) in group A and in 31 patients (52%) in group B.,Family history was positive in 33 patients (55%) in group A and in 31 patients (52%) in group B.,100.0
1465,10.1016/j.athoracsur.2018.05.023,Eligibility,All patients tried medical treatment before referral to surgery in both groups.,All patients tried medical treatment before referral to surgery in both groups,100.0
1465,10.1016/j.athoracsur.2018.05.023,Recruitment,"Between October 2012 and August 2016, a prospective study was designed with a total number of 120 patients with primary palmar and axillary hyperhidrosis after approval from the Institutional Ethics Committee.","Between October 2012 and August 2016, a prospective study was designed with a total number of 120 patients with primary palmar and axillary hyperhidrosis after approval from the Institutional Ethics Committee.",100.0
1465,10.1016/j.athoracsur.2018.05.023,Recruitment,Patients were randomly divided into 2 groups: group A and group B.,Patients were randomly divided into 2 groups: group A and group B.,100.0
1465,10.1016/j.athoracsur.2018.05.023,Recruitment,Randomization was done by using a computer program called the Random Number Generator.,Randomization was done by using a computer program called the Random Number Generator,100.0
1465,10.1016/j.athoracsur.2018.05.023,Setting,Bilateral and sequential sympathectomy were performed in all cases in the same setting.,Bilateral and sequential sympathectomy were performed in all cases in the same setting.,100.0
1465,10.1016/j.athoracsur.2018.05.023,Setting,Double lumen endotracheal intubation with general anesthesia is the standard technique.,Double lumen endotracheal intubation with general anesthesia is the standard technique.,100.0
1465,10.1016/j.athoracsur.2018.05.023,Setting,Patients are discharged only after confirming full lung reexpansion.,Patients are discharged only after confirming full lung reexpansion.,100.0
1465,10.1016/j.athoracsur.2018.05.023,Organisation,"There were no major complications, perioperative mortality, or conversion to thoracotomy.","There were no major complications, perioperative mortality, or conversion to thoracotomy.",100.0
1465,10.1016/j.athoracsur.2018.05.023,Organisation,"Only 1 patient (1.7%) in group A and 1 patient (1.7%) in group B (p = 1) developed mild surgical site infection, which was treated by daily dressing and local antibiotics for 5 days.","Only 1 patient (1.7%) in group A and 1 patient (1.7%) in group B (p = 1) developed mild surgical site infection, which was treated by daily dressing and local antibiotics for 5 days",100.0
1465,10.1016/j.athoracsur.2018.05.023,Organisation,No patient developed Horner syndrome or gustatory sweating throughout the entire follow-up period.,No patient developed Horner syndrome or gustatory sweating throughout the entire follow-up period.,100.0
1465,10.1016/j.athoracsur.2018.05.023,Flexibility (delivery),"Sympathectomy was carried out by electrocoagulation hook at levels T2, T3, and T4 in group A and at level T3 and T4 in group B.","Sympathectomy was carried out by electrocoagulation hook at levels T2, T3, and T4 in group A and at level T3 and T4 in group B.",100.0
1465,10.1016/j.athoracsur.2018.05.023,Flexibility (delivery),Hand temperature monitoring is done routinely.,Hand temperature monitoring is done routinely.,100.0
1465,10.1016/j.athoracsur.2018.05.023,Flexibility (delivery),"After endoscopic confirmation of full lung reexpansion, a chest tube is removed.","After endoscopic confirmation of full lung reexpansion, a chest tube is removed.",100.0
1465,10.1016/j.athoracsur.2018.05.023,Follow-up,Data on patient reported outcomes were collected by regular visits in outpatient clinic and by direct telephone contact.,Data on patient reported outcomes were collected by regular visits in outpatient clinic and by direct telephone contact.,100.0
1465,10.1016/j.athoracsur.2018.05.023,Follow-up,There were no missing data for these variables.,There were no missing data for these variables.,100.0
1465,10.1016/j.athoracsur.2018.05.023,Follow-up,Patients were examined for the development of overdry hands and compensatory sweating.,patients were examined for the development of overdry hands and compensatory sweating,100.0
1465,10.1016/j.athoracsur.2018.05.023,Primary outcome,All patients had improvement of hand sweating.,All patients had improvement of hand sweating.,100.0
1465,10.1016/j.athoracsur.2018.05.023,Primary outcome,"Limited sympathectomy to the level of T3 and T4 has the same therapeutic effect obtained by T2, T3, and T4 sympathectomy with less complications, greater patient satisfaction, and better quality of life.","Limited sympathectomy to the level of T3 and T4 has the same therapeutic effect obtained by T2, T3, and T4 sympathectomy with less complications, greater patient satisfaction, and better quality of life.",100.0
1465,10.1016/j.athoracsur.2018.05.023,Primary outcome,It should be the technique of choice for treatment of primary palmar and axillary hyperhidrosis.,It should be the technique of choice for treatment of primary palmar and axillary hyperhidrosis.,100.0
1465,10.1016/j.athoracsur.2018.05.023,Primary analysis,Results are given as mean ± SD.,Results are given as mean ± SD.,100.0
1465,10.1016/j.athoracsur.2018.05.023,Primary analysis,"Significance between the 2 groups was determined by chi-square test comparing patients' data, complications, and patients' satisfaction.","Significance between the 2 groups was determined by chi-square test comparing patients' data, complications, and patients' satisfaction.",100.0
1465,10.1016/j.athoracsur.2018.05.023,Primary analysis,A p value of less than 0.05 was considered significant.,A p value of less than 0.05 was considered significant.,100.0
710,10.1186/s12931-015-0170-1,Eligibility,"The inclusion criteria were: [1] admission due to AECOPD, [2] COPD (GOLD stage III or IV, 2007), [3] living in the Trondheim municipality, [4] an ability to communicate in Norwegian, and [5] an ability to sign the informed consent form.","The inclusion criteria were: [1] admission due to AECOPD, [2] COPD (GOLD stage III or IV, 2007), [3] living in the Trondheim municipality, [4] an ability to communicate in Norwegian, and [5] an ability to sign the informed consent form.",100.0
710,10.1186/s12931-015-0170-1,Eligibility,The exclusion criterion was: [1] any serious diseases that might cause a very short lifespan (expected survival time less than six months).,The exclusion criterion was: [1] any serious diseases that might cause a very short lifespan (expected survival time less than six months).,100.0
710,10.1186/s12931-015-0170-1,Recruitment,All participants were recruited from the DTM or the Observation Unit (OU) at the TUH.,All participants were recruited from the DTM or the Observation Unit (OU) at the TUH.,100.0
710,10.1186/s12931-015-0170-1,Recruitment,The study nurses contacted all patients hospitalized at the DTM or the OU because of AECOPD and invited them to participate in the study provided their home address was in the municipality of Trondheim.,The study nurses contacted all patients hospitalized at the DTM or the OU because of AECOPD and invited them to participate in the study provided their home address was in the municipality of Trondheim.,100.0
710,10.1186/s12931-015-0170-1,Setting,"A single centre, prospective, open, controlled clinical study comparing COPD-Home integrated care (IC) with usual care (UC).","A single centre, prospective, open, controlled clinical study comparing COPD-Home integrated care (IC) with usual care (UC).",100.0
710,10.1186/s12931-015-0170-1,Organisation,The COPD-Home integrated care model reduced hospital utilization in patients with COPD III and IV with a persisting effect throughout the 2 years of follow-up., according to the COPD-Home model reduced hospital utilization in patients with COPD III and IV with a persisting effect throughout the 2 years of follow-up. ,89.87341772151899
710,10.1186/s12931-015-0170-1,Flexibility (delivery),"The core elements of the COPD-Home model were: [1] a call centre staffed by three specialist nurses for support and communication with patients and home-care nurses, and coordination between the various levels of care.","The core elements of the COPD-Home model were: [1] a call centre staffed by three specialist nurses for support and communication with patients and home-care nurses, and coordination between the various levels of care.",100.0
710,10.1186/s12931-015-0170-1,Flexibility (delivery),An individualized self-management plan introduced to the patient at discharge by the treating doctor and a specialist nurse.,an individualized self-management plan introduced to the patient at discharge by the treating doctor and a specialist nurse,100.0
710,10.1186/s12931-015-0170-1,Flexibility (delivery),"Joint visits at the patients home by the specialist nurse (together with the home-care nurse for participants receiving home services) at approximately three days, 14 days, six months, 12 months and 24 months post-discharge.","joint visits at the patients home by the specialist nurse (together with the home-care nurse for participants receiving home services) at approximately three days, 14 days, six months, 12 months and 24 months post-discharge",100.0
710,10.1186/s12931-015-0170-1,Flexibility (adherence),"All participants included in the COPD-Home study were free to use all available medical services, including their GPs.","All participants included in the COPD-Home study were free to use all available medical services, including their GPs.",100.0
710,10.1186/s12931-015-0170-1,Follow-up,"After two years of follow-up, a total of 100 patients (58% of the included patients), 51 patients in the IC group and 49 patients in the UC group, were available for evaluation.","After two years of follow-up, a total of 100 patients (58% of the included patients), 51 patients in the IC group and 49 patients in the UC group, were available for evaluation",100.0
710,10.1186/s12931-015-0170-1,Primary outcome,The primary outcomes were: [1] Number of hospital admissions caused by AECOPD (HA) and [2] number of in-hospital days (HD) due to AECOPD.,The primary outcomes were: [1] Number of hospital admissions caused by AECOPD (HA) and [2] number of in-hospital days (HD) due to AECOPD.,100.0
710,10.1186/s12931-015-0170-1,Primary analysis,Data from patients who completed a minimum of two years of follow-up were included in the analysis.,Data from patients who completed a minimum of two years of follow-up were included in the analysis.,100.0
1594,10.1002/art.24106,Eligibility,Patients with RA for <2 years who had never taken MTX and who self-reported work impairment were randomized to adalimumab + MTX or placebo + MTX for 56 weeks.,patients with RA for <2 years who had never taken MTX and who self-reported work impairment were randomized to adalimumab + MTX or placebo + MTX for 56 weeks,100.0
1594,10.1002/art.24106,Eligibility,"Patients with active infections (including tuberculosis), previous malignancy, and uncontrolled concomitant illness were excluded.","Patients with active infections (including tuberculosis), previous malignancy, and uncontrolled concomitant illness were excluded.",100.0
1594,10.1002/art.24106,Eligibility,"Other exclusion criteria comprised long-term sick leave, inflammatory arthritis other than RA, juvenile RA, significantly abnormal laboratory results, pregnancy/breastfeeding, human immunodeficiency virus infection, other chronic infections, demyelination, and inability to give informed consent.","Other exclusion criteria comprised long-term sick leave, inflammatory arthritis other than RA, juvenile RA, significantly abnormal laboratory results, pregnancy/breastfeeding, human immunodeficiency virus infection, other chronic infections, demyelination, and inability to give informed consent.",100.0
1594,10.1002/art.24106,Recruitment,"During the recruitment period (March 5, 2003 through December 2, 2004), 162 patients were screened and 148 were randomized to adalimumab + MTX (n = 75) or placebo + MTX (n = 73).","During the recruitment period (March 5, 2003 through December 2, 2004), 162 patients were screened and 148 were randomized to adalimumab + MTX (n = 75) or placebo + MTX (n = 73).",100.0
1594,10.1002/art.24106,Setting,"This was a 56-week, multicenter, randomized, double-blind, placebo-controlled study.","This was a 56-week, multicenter, randomized, double-blind, placebo-controlled study.",100.0
1594,10.1002/art.24106,Organisation,"Treatment was well tolerated, with no significant differences between the groups. There were no cases of malignancies or tuberculosis. Our study had the same percentage of patients with serious adverse events (11%) as the ASPIRE study. The rates of serious adverse events were 21.0 and 20.5 events/100 patient-years, compared with 15.9 and 18.5 for placebo + MTX and adalimumab + MTX, respectively, in the PREMIER study (which additionally reported 21.1 in the adalimumab-only arm). Serious infections were marginally higher in the current study, but with no difference between the groups.","Treatment was well tolerated, with no significant differences between the groups. There were no cases of malignancies or tuberculosis. Our study had the same percentage of patients with serious adverse events (11%) as the ASPIRE study. The rates of serious adverse events were 21.0 and 20.5 events/100 patient-years, compared with 15.9 and 18.5 for placebo + MTX and adalimumab + MTX, respectively, in the PREMIER study (which additionally reported 21.1 in the adalimumab-only arm). Serious infections were marginally higher in the current study, but with no difference between the groups.",100.0
1594,10.1002/art.24106,Flexibility (delivery),"The blind was maintained at all times until data collection was finished and the database was locked, except for 1 patient who became pregnant for whom the blind was broken earlier.","The blind was maintained at all times until data collection was finished and the database was locked, except for 1 patient who became pregnant for whom the blind was broken earlier.",100.0
1594,10.1002/art.24106,Flexibility (adherence),"Rules for participant withdrawal from the trial included job loss, imminent job loss, and adverse events (at the discretion of the physician). Physicians had the ability to withdraw patients due to an unacceptably high disease activity in the interest of the patient's care.","Rules for participant withdrawal from the trial included job loss, imminent job loss, and adverse events (at the discretion of the physician). Physicians had the ability to withdraw patients due to an unacceptably high disease activity in the interest of the patient's care.",100.0
1594,10.1002/art.24106,Follow-up,"This was a 56-week, multicenter, randomized, double-blind, placebo-controlled study.","This was a 56-week, multicenter, randomized, double-blind, placebo-controlled study.",100.0
1594,10.1002/art.24106,Primary outcome,"The primary end point of the study was job loss of any cause and/or imminent job loss, defined as a failure to achieve an ACR 20% (ACR20) response at/after week 16 and either a WIS score deterioration from baseline or a persistently high WIS score (>17).","The primary end point of the study was job loss of any cause and/or imminent job loss, defined as a failure to achieve an ACR 20% (ACR20) response at/after week 16 and either a WIS score deterioration from baseline or a persistently high WIS score (>17).",100.0
1594,10.1002/art.24106,Primary analysis,"According to the statistical analysis plan finalized before database lock, missing values for the primary end point (e.g., participants who discontinued the study prior to week 56 without having been affected by job loss/imminent job loss) were to be classified as no job loss/imminent job loss for the primary analysis.","According to the statistical analysis plan finalized before database lock, missing values for the primary end point (e.g., participants who discontinued the study prior to week 56 without having been affected by job loss/imminent job loss) were to be classified as no job loss/imminent job loss for the primary analysis.",100.0
1139,10.1016/s0140-6736(18)30298-8,Eligibility,"Exclusion criteria were recurrent umbilical hernia, incarcerated umbilical hernia, incisional hernia or epigastric hernia, an American Society of Anesthesiologists (ASA) classification higher than ASA III, or one or more of the following diseases in their medical history: midline laparotomy, laparoscopy with an umbilical entrance port, ascites, peritoneal dialysis, or liver cirrhosis.","Exclusion criteria were recurrent umbilical hernia, incarcerated umbilical hernia, incisional hernia or epigastric hernia, an American Society of Anesthesiologists (ASA) classification higher than ASA III, or one or more of the following diseases in their medical history: midline laparotomy, laparoscopy with an umbilical entrance port, ascites, peritoneal dialysis, or liver cirrhosis.",100.0
1139,10.1016/s0140-6736(18)30298-8,Eligibility,"Patients who visited the outpatient clinic with an umbilical hernia received an information package about our trial. If patients decided to undergo an operation, they were recruited for the trial as well.","Patients who visited the outpatient clinic with an umbilical hernia received an information package about our trial. If patients decided to undergo an operation, they were recruited for the trial as well.",100.0
1139,10.1016/s0140-6736(18)30298-8,Eligibility,"We did a randomised, double-blind, controlled multicentre trial in 12 hospitals (nine in the Netherlands, two in Germany, and one in Italy).","We did a randomised, double-blind, controlled multicentre trial in 12 hospitals (nine in the Netherlands, two in Germany, and one in Italy).",100.0
1139,10.1016/s0140-6736(18)30298-8,Eligibility,"At the start of the study, all surgeons were invited to specific trial training sessions, which were organised in the surgical SkillsLab of the coordinating centre (Erasmus University Medical Center, Rotterdam, Netherlands) to ensure that all participating surgeons would use the same standardised techniques to close an umbilical hernia.","At the start of the study, all surgeons were invited to specific trial training sessions, which were organised in the surgical SkillsLab of the coordinating centre (Erasmus University Medical Center, Rotterdam, Netherlands) to ensure that all participating surgeons would use the same standardised techniques to close an umbilical hernia.",100.0
1139,10.1016/s0140-6736(18)30298-8,Eligibility,"Suture repair of the umbilical defect consisted of adaptation of the fascia in the midline by either interrupted or continuous, non-absorbable, monofilament, polypropylene sutures of thickness 0/0 (monofilament Prolene suture). Sutures were placed in a transverse direction.","Suture repair of the umbilical defect consisted of adaptation of the fascia in the midline by either interrupted or continuous, non-absorbable, monofilament, polypropylene sutures of thickness 0/0 (monofilament Prolene suture). Sutures were placed in a transverse direction.",100.0
1139,10.1016/s0140-6736(18)30298-8,Eligibility,Postoperative analgesics could consist of diclofenac 50 mg three times daily and paracetamol 1000 mg three times daily (or equivalent) administered orally for 6 days after surgery.,Postoperative analgesics could consist of diclofenac 50 mg three times daily and paracetamol 1000 mg three times daily (or equivalent) administered orally for 6 days after surgery.,100.0
1139,10.1016/s0140-6736(18)30298-8,Eligibility,"Patients underwent physical examinations at 2 weeks, and 3, 12, and 24–30 months after the operation.","Patients underwent physical examinations at 2 weeks, and 3, 12, and 24–30 months after the operation.",100.0
1139,10.1016/s0140-6736(18)30298-8,Eligibility,"The primary outcome was the rate of recurrences of the umbilical hernia after 24 months assessed in the modified intention-to-treat population by physical examination and, in case of any doubt, abdominal ultrasound.","The primary outcome was the rate of recurrences of the umbilical hernia after 24 months assessed in the modified intention-to-treat population by physical examination and, in case of any doubt, abdominal ultrasound.",100.0
1139,10.1016/s0140-6736(18)30298-8,Eligibility,"All analyses were done according to intention-to-treat principles; ie, analysed according to the treatment group that patients were assigned to.","All analyses were done according to intention-to-treat principles; ie, analysed according to the treatment group that patients were assigned to.",100.0
1614,10.1016/j.homp.2011.03.002,Eligibility,Children with AOM were enrolled in the study at the time of diagnosis and randomized to receive either standard therapy alone or standard therapy plus a homeopathic ear drop solution that was to be used on as needed basis for up to 5 days.,Children with AOM were enrolled in the study at the time of diagnosis and randomized to receive either standard therapy alone or standard therapy plus a homeopathic ear drop solution that was to be used on as needed basis for up to 5 days.,100.0
1614,10.1016/j.homp.2011.03.002,Eligibility,"Children with a chronic medical condition, those who had received antibiotics within the previous 2 days, had a diagnosis of AOM during the preceding 30 days, or who had a perforated tympanic membrane were excluded.","Children with a chronic medical condition, those who had received antibiotics within the previous 2 days, had a diagnosis of AOM during the preceding 30 days, or who had a perforated tympanic membrane were excluded.",100.0
1614,10.1016/j.homp.2011.03.002,Eligibility,"In addition, children who had received any homeopathic medicine during the previous 30 days were not enrolled.","In addition, children who had received any homeopathic medicine during the previous 30 days were not enrolled.",100.0
1614,10.1016/j.homp.2011.03.002,Recruitment,Parents of children in both treatment groups rated the severity of 5 AOM symptoms twice daily for 5 days in a symptom diary.,Parents of children in both treatment groups rated the severity of 5 AOM symptoms twice daily for 5 days in a symptom diary.,100.0
1614,10.1016/j.homp.2011.03.002,Recruitment,Symptom diaries were received from 94 (79%).,symptom diaries were received from 94 (79,100.0
1614,10.1016/j.homp.2011.03.002,Setting,"The study was conducted at the University of Washington Medical Center Pediatric Care Center, a comprehensive primary care clinic that is a major training site for pediatric residents.","The study was conducted at the University of Washington Medical Center Pediatric Care Center, a comprehensive primary care clinic that is a major training site for pediatric residents.",100.0
1614,10.1016/j.homp.2011.03.002,Organisation,"The homeopathic ear drops, Hylands Earache Drops, used in the study are commercially available in the United States.","The homeopathic ear drops, Hylands Earache Drops, used in the study are commercially available in the United State",99.1304347826087
1614,10.1016/j.homp.2011.03.002,Organisation,Parents of children randomized to the ear drops were instructed to administer 3-4 drops up to 3 times/day as needed for relief of AOM symptoms for a maximum of 5 days.,Parents of children randomized to the ear drops were instructed to administer 3e4 drops up to 3 times/day as needed for relief of AOM symptoms for a maximum of 5 days,99.3975903614458
1614,10.1016/j.homp.2011.03.002,Flexibility (delivery),Parents of all study patients were asked to complete a symptom severity diary twice daily for the first 5 days after enrollment.,rents of all study patients were asked to complete a symptom severity diary twice daily (at 8 am and 8 pm) for the first 5 days,85.03937007874016
1614,10.1016/j.homp.2011.03.002,Flexibility (delivery),"Regardless of group assignment, parents of all study patients were asked to complete a symptom severity diary twice daily for the first 5 days after enrollment."," of group assignment, parents of all study patients were asked to complete a symptom severity diary twice daily (at 8 am and 8 pm) for the first 5 days after e",88.0503144654088
1614,10.1016/j.homp.2011.03.002,Flexibility (adherence),Parents of children randomized to the ear drops were given an ear drop dosage diary. Parents were asked to record data on up to the first 6 doses of ear drops administered to their children.,to standard therapy plus homeopathic ear drops were given an ear drop dosage diary. Parents were asked to record data on up to the first 6 doses of ear drops administered to their children.,87.83068783068784
1614,10.1016/j.homp.2011.03.002,Flexibility (adherence),Data on the responses to individual doses of the ear drops were analyzed.,data on the responses to individual doses of the ear drops were analyzed,100.0
1614,10.1016/j.homp.2011.03.002,Follow-up,Parents of study children were contacted by telephone for a follow-up assessment. During this telephone interview parents were asked about any further visits to health care providers and if they filled the antibiotic prescription and gave it to their child., parents of study children were contacted by telephone for a followup assessment. During this telephone interview parents were asked about any further visits to health care providers and if they filled the antibiotic prescription and gave it to their child,99.609375
1614,10.1016/j.homp.2011.03.002,Follow-up,"Functional status, based on FSIIR scores, was similar among children randomized to ear drops plus standard therapy and in those receiving standard therapy alone.","Functional status, based on FSIIR scores, was similar among children randomized to ear drops plus standard therapy and in those receiving standard therapy alone",100.0
1614,10.1016/j.homp.2011.03.002,Primary outcome,"A total of 119 eligible children were enrolled in the study; symptom diaries were received from 94 (79%). Symptom scores tended to be lower in the group of children receiving ear drops than in those receiving standard therapy alone; these differences were significant at the second and third assessments (P = 0.04 and P = 0.003, respectively).","A total of 119 eligible children were enrolled in the study; symptom diaries were received from 94 (79%). Symptom scores tended to be lower in the group of children receiving ear drops than in those receiving standard therapy alone; these differences were significant at the second and third assessments (P = 0.04 and P = 0.003, respectively).",100.0
1614,10.1016/j.homp.2011.03.002,Primary analysis,Mann-Whitney tests were used to assess the statistical significance of differences in ETG-5 scores between children randomized to ear drops and those receiving standard therapy alone.,Mann-Whitney tests were used to assess the statistical significance of differences in ETG-5 scores between children randomized to ear drops and those receiving standard therapy alone.,100.0
1614,10.1016/j.homp.2011.03.002,Primary analysis,"Linear mixed models were conducted to examine change in ETG total score over time (ratings) by treatment group, standard therapy alone vs. standard therapy plus ear drops controlling for baseline ETG total score.","linear mixed models were conducted to examine change in ETG total score over time (ratings) by treatment group, standard therapy alone vs. standard therapy plus ear drops controlling for baseline ETG total score",100.0
1767,10.1001/jama.202.11.1028,Eligibility,"Also excluded from the study were patients with surgically curable hypertension, uremia, and concomitant fatal diseases such as carcinoma. Patients with hemorrhages, exudates, or papilledema in the optic fundi, history of cerebral or subarachnoid hemorrhage, dissecting aneurysm, or congestive heart failure resistant to digitalis and mercurial diuretics were excluded. Additional exclusions included patients who wished to return to the care of their private physicians, those who for geographical or other reasons would be unable to attend clinic regularly, and patients of dubious reliability such as alcoholics, vagrants, and poorly motivated patients.","Also excluded from the study were patients with surgically curable hypertension, uremia, and concomitant fatal diseases such as carcinoma. Patients with hemorrhages, exudates, or papilledema in the optic fundi, history of cerebral or subarachnoid hemorrhage, dissecting aneurysm, or congestive heart failure resistant to digitalis and mercurial diuretics were excluded. Additional exclusions included patients who wished to return to the care of their private physicians, those who for geographical orother reasons would be unable to attend clinic regularly, and patients of dubious reliability such as alcoholics, vagrants, and poorly motivated patients.",99.84732824427482
1767,10.1001/jama.202.11.1028,Eligibility,Only the patients whose diastolic blood pressures averaged 115 to 129 mm Hg during the last two prerandomization clinic visits are included in the present report.,Only the patients whose diastolic blood pressures averaged 115 to 129 mm Hg during the last two prerandomization clinic visits are included in the present report.,100.0
1767,10.1001/jama.202.11.1028,Eligibility,For this high-risk group the study was ended in May 1967. The patients with lower prerandomization diastolic readings are continuing in the study and will be reported on later.,For this high-risk group the study was ended in May 1967. The patients with lower prerandomization diastolic readings are continuing in the study and will be reported on later.,100.0
1767,10.1001/jama.202.11.1028,Recruitment,All patients were hospitalized for the initial workup. Male patients whose diastolic blood pressures from the fourth through the sixth day of hospitalization averaged 90 through 129 mm Hg without treatment were considered for admission to the prerandomization trial period.,All patients were hospitalized for the initial workup. Male patients whose diastolic blood pressures from the fourth through the sixth day of hospitalization averaged 90 through 129 mm Hg without treatment were considered for admission to the prerandomization trial period.,100.0
1767,10.1001/jama.202.11.1028,Recruitment,"Following discharge from the hospital, the patients entered a prerandomization trial period of two to four months' duration. They received two placebos, known to the physician but not to the patient, and were seen in the clinic at monthly intervals.","Following discharge from the hospital, the patients entered a prerandomization trial period of two to four months' duration. They received two placebos, known to the physician but not to the patient, and were seen in the clinic at monthly intervals.",100.0
1767,10.1001/jama.202.11.1028,Recruitment,"To qualify for admission to the study, the patients were required to have no 'violations' on two successive clinic visits. A violation consisted either of failure to appear at the regularly scheduled clinic appointment, or failure of the urine to exhibit fluorescence, or a tablet count (of either of the two types of placebos) which was outside the acceptable range.","To qualify for admission to the study, the patients were required to have no ""violations"" on two successive clinic visits. A violation consisted either of failure to appear at the regularly scheduled clinic appointment, or failure of the urine to exhibit fluorescence, or a tablet count (of either of the two types of placebos) which was outside the acceptable range",100.0
1767,10.1001/jama.202.11.1028,Setting,The patients visited the clinic at monthly intervals for the first two months following randomization and at bimonthly intervals henceforth. Additional interim visits were scheduled if needed.,The patients visited the clinic at monthly intervals for the first two months following randomization and at bimonthly intervals henceforth. Additional interim visits were scheduled if needed.,100.0
1767,10.1001/jama.202.11.1028,Setting,The 143 patients were admitted into the study from April 1964 to December 1966. Observations on all these patients ended in May 1967.,The 143 patients were admitted into the study from April 1964 to December 1966. Observations on all these patients ended in May 1967.,100.0
1767,10.1001/jama.202.11.1028,Organisation,"Treatment was begun with either tablet A, one twice daily, plus the 25-mg tablet B, one tablet three times daily, or else with the placebos of both of these tablets.","Treatment was begun with either tablet A, one twice daily, plus the 25-mg tablet B, one tablet three times daily, or else with the placebos of both of these tablets.",100.0
1767,10.1001/jama.202.11.1028,Organisation,Dosages were reduced in the remaining patients because of low blood pressure levels with the standard regimen or because of side effects such as severe headache or weakness.,Dosages were reduced in the remaining patients because of low blood pressure levels with the standard regimen or because of side effects such as severe headache or weakness.,100.0
1767,10.1001/jama.202.11.1028,Organisation,"In order to further minimize losses due to drug toxicity, two special A tablets were available on request. One contained hydrochlorothiazide without reserpine for patients becoming depressed or having active peptic ulcer or other reserpine-associated severe side effects. The other contained reserpine without hydrochlorothiazide for toxicity associated with the latter, such as hyperglycemia or acute gout.","In order to further minimize losses due to drug toxicity, two special A tablets were available on request. One contained hydrochlorothiazide without reserpine for patients becoming depressed or having active peptic ulcer or other reserpine-associated severe side effects. The other contained reserpine without hydrochlorothiazide for toxicity associated with the latter, such as hyperglycemia or acute gout.",100.0
1767,10.1001/jama.202.11.1028,Flexibility (delivery),"Treatment was begun with either tablet A, one twice daily, plus the 25-mg tablet B, one tablet three times daily, or else with the placebos of both of these tablets.","Treatment was begun with either tablet A, one twice daily, plus the 25-mg tablet B, one tablet three times daily, or else with the placebos of both of these tablets.",100.0
1767,10.1001/jama.202.11.1028,Flexibility (delivery),"However, if there were hypotensive reactions or other severe side effects, doses could be reduced to a tolerable level.","wever, if there were hypo- tensive reactions or other severe side effects, doses could be reduced to a tolerable level",98.30508474576271
1767,10.1001/jama.202.11.1028,Flexibility (delivery),"In order to further minimize losses due to drug toxicity, two special A tablets were available on request. One contained hydrochlorothiazide without reserpine for patients becoming depressed or having active peptic ulcer or other reserpine-associated severe side effects. The other contained reserpine without hydrochlorothiazide for toxicity associated with the latter, such as hyperglycemia or acute gout.","In order to further minimize losses due to drug toxicity, two special A tablets were available on request. One contained hydrochlorothiazide without reserpine for patients becoming depressed or having active peptic ulcer or other reserpine-associated severe side effects. The other contained reserpine without hydrochlorothiazide for toxicity associated with the latter, such as hyperglycemia or acute gout.",100.0
1767,10.1001/jama.202.11.1028,Follow-up,The patients visited the clinic at monthly intervals for the first two months following randomization and at bimonthly intervals henceforth. Additional interim visits were scheduled if needed.,The patients visited the clinic at monthly intervals for the first two months following randomization and at bimonthly intervals henceforth. Additional interim visits were scheduled if needed.,100.0
1767,10.1001/jama.202.11.1028,Follow-up,"Annual examinations included complete physical examination, roentgenogram of the chest, electrocardiogram, blood chemistry, and renal function tests.","Annual examinations included complete physical examination, roentgenogram of the chest, electrocardiogram, blood chemistry, and renal function tests.",100.0
1767,10.1001/jama.202.11.1028,Follow-up,Tablet counts were made at all clinic visits and fluorescence tests of the urine were made at alternate visits.,Tablet counts were made at all clinic visits and fluorescence tests of the urine were made at alternate visits.,100.0
1155,10.1016/s0140-6736(13)62419-8,Eligibility,"Women with monochorionic, diamniotic twin pregnancies up to 26 weeks' gestation complicated by twin-to-twin transfusion syndrome (Quintero stage16 2, 3, or 4) and women with Quintero stage 1 with clinical symptoms from polyhydramnios were eligible for participation in the trial.","Women with monochorionic, diamniotic twin pregnancies up to 26 weeks' gestation complicated by twin-to-twin transfusion syndrome (Quintero stage16 2, 3, or 4) and women with Quintero stage 1 with clinical symptoms from polyhydramnios were eligible for participation in the trial.",100.0
1155,10.1016/s0140-6736(13)62419-8,Eligibility,Exclusion criteria consisted of triplet pregnancies and mothers who were unable to provide informed consent.,Exclusion criteria consisted of triplet pregnancies and mothers who were unable to provide informed consent.,100.0
1155,10.1016/s0140-6736(13)62419-8,Recruitment,Women were informed about the study by their obstetrician after they were planned for fetoscopic laser therapy.,Women were informed about the study by their obstetrician after they were planned for fetoscopic laser therapy.,100.0
1155,10.1016/s0140-6736(13)62419-8,Setting,"We did an open-label, international, multicentre, randomised controlled trial at five European tertiary referral centres.","We did an open-label, international, multicentre, randomised controlled trial at five European tertiary referral centres",100.0
1155,10.1016/s0140-6736(13)62419-8,Organisation,"All fetoscopic laser procedures were undertaken by experienced operators (12 surgeons), each of whom had done at least 60 previous laser procedures and were competent to undertake the Solomon technique.","All fetoscopic laser procedures were undertaken by experienced operators (12 surgeons), each of whom had done at least 60 previous laser procedures and were competent to undertake the Solomon technique.",100.0
1155,10.1016/s0140-6736(13)62419-8,Flexibility (delivery),The following steps were identical for both the experimental and the standard procedure.,The following steps were identical for both the experimental and the standard procedure.,100.0
1155,10.1016/s0140-6736(13)62419-8,Follow-up,"Follow-up visits, including an ultrasound assessment, were scheduled a minimum of once every 2 weeks.","Follow-up visits, including an ultrasound assessment, were scheduled a minimum of once every 2 weeks.",100.0
1155,10.1016/s0140-6736(13)62419-8,Primary outcome,"The primary outcome was a composite of incidence of twin anaemia polycythaemia sequence, recurrence of twin-to-twin transfusion syndrome, perinatal mortality, or severe neonatal morbidity.","The primary outcome was a composite of incidence of twin anaemia polycythaemia sequence, recurrence of twin-to-twin transfusion syndrome, perinatal mortality, or severe neonatal morbidity.",100.0
1155,10.1016/s0140-6736(13)62419-8,Primary analysis,"Analyses were done by intention to treat, with results expressed as odds ratios (ORs) and 95% CIs."," Analyses were by intention to treat, with results expressed as odds ratios (ORs) and 95% CIs. Th",94.84536082474226
1199,10.1016/j.arthro.2010.11.059,Eligibility,"Inclusion criteria for this study were (1) a full-thickness rotator cuff tear proven by preoperative magnetic resonance imaging (MRI) or magnetic resonance arthrography, (2) symptoms lasting more than 6 months with proper conservative treatment, and (3) a 2- to 4-cm tear size in either the coronal or sagittal plane, which was measured and confirmed intraoperatively.","Inclusion criteria for this study were (1) a full-thickness rotator cuff tear proven by preoperative magnetic resonance imaging (MRI) or magnetic resonance arthrography, (2) symptoms lasting more than 6 months with proper conservative treatment, and (3) a 2- to 4-cm tear size in either the coronal or sagittal plane, which was measured and confirmed intraoperatively.",100.0
1199,10.1016/j.arthro.2010.11.059,Eligibility,"Exclusion criteria were (1) a rotator cuff tear in which either SR or DR repair was not possible; (2) a cuff tear in which complete footprint coverage was impossible; (3) any history of prior surgery, fracture, dislocation, or infection of the affected shoulder; (4) inflammatory joint disease of the affected shoulder, including rheumatoid arthritis; and (5) an open repair, including an open repair of the subscapularis.","Exclusion criteria were (1) a rotator cuff tear in which either SR or DR repair was not possible; (2) a cuff tear in which complete footprint coverage was impossible; (3) any history of prior surgery, fracture, dislocation, or infection of the affected shoulder; (4) inflammatory joint disease of the affected shoulder, including rheumatoid arthritis; and (5) an open repair, including an open repair of the subscapularis.",100.0
1199,10.1016/j.arthro.2010.11.059,Recruitment,"From December 2005 to March 2007, arthroscopic rotator cuff repair was performed in 184 shoulders. Eighty-eight patients met the inclusion criteria, but seventeen were excluded. A total of 71 rotator cuff tears were repaired with either the SR or DR repair technique.","From December 2005 to March 2007, arthroscopic rotator cuff repair was performed in 184 shoulders. Eighty-eight patients met the inclusion criteria, but seventeen were excluded. A total of 71 rotator cuff tears were repaired with either the SR or DR repair technique.",100.0
1199,10.1016/j.arthro.2010.11.059,Setting,Surgeries were performed by a single surgeon (J.C.Y.) with the patient under general anesthesia in the lateral decubitus position.,Surgeries were performed by a single surgeon (J.C.Y.) with the patient under general anesthesia in the lateral decubitus position.,100.0
1199,10.1016/j.arthro.2010.11.059,Organisation,"No statistical differences were found between the 2 groups in terms of preoperative demographic data, including, age, sex, dominant arm, involved shoulder, or symptom duration.","No statistical differences were found between the 2 groups in terms of preoperative demographic data, including, age, sex, dominant arm, involved shoulder, or symptom duration.",100.0
1199,10.1016/j.arthro.2010.11.059,Flexibility (delivery),Surgeries were performed by a single surgeon (J.C.Y.) with the patient under general anesthesia in the lateral decubitus position.,Surgeries were performed by a single surgeon (J.C.Y.) with the patient under general anesthesia in the lateral decubitus position.,100.0
1199,10.1016/j.arthro.2010.11.059,Flexibility (adherence),Rehabilitation protocols were identical for all study subjects.,Rehabilitation protocols were identical for all study subjects.,100.0
1199,10.1016/j.arthro.2010.11.059,Follow-up,"The SR group was followed up for 31.0 months (range, 24 to 44 months) and the DR group for 32.8 months (range, 24 to 42 months).","The SR group was followed up for 31.0 months (range, 24 to 44 months) and the DR group for 32.8 months (range, 24 to 42 months).",100.0
1199,10.1016/j.arthro.2010.11.059,Primary outcome,This study showed that DR repair with 1 additional medial suture anchor and 2 added stitches for rotator cuff repair produced no difference in terms of clinical outcome or retear rate compared with SR repair for medium to large (2- to 4-cm) rotator cuff tears.,This study showed that DR repair with 1 additional medial suture anchor and 2 added stitches for rotator cuff repair produced no difference in terms of clinical outcome or retear rate compared with SR repair for medium to large (2- to 4-cm) rotator cuff tears.,100.0
1199,10.1016/j.arthro.2010.11.059,Primary analysis,"Retears were classified by use of the criteria of Sugaya et al.21, 27 into 5 types: type I, the repaired cuff appeared to have sufficient thickness as compared with the normal cuff and had homogeneous low intensity on each image; type II, sufficient thickness as compared with the normal cuff associated with a partial high-intensity area; type III, insufficient cuff thickness (less than half that of the normal cuff) but without discontinuity, suggesting a partial-thickness delaminated tear; type IV, presence of a minor discontinuity in only 1 or 2 slices on both oblique coronal and sagittal images, suggesting a small full-thickness tear; and type V, presence of a major discontinuity observed in more than 2 slices on both oblique coronal and sagittal images.","Retears were classified by use of the criteria of Sugaya et al.21, 27 into 5 types: type I, the repaired cuff appeared to have sufficient thickness as compared with the normal cuff and had homogeneous low intensity on each image; type II, sufficient thickness as compared with the normal cuff associated with a partial high-intensity area; type III, insufficient cuff thickness (less than half that of the normal cuff) but without discontinuity, suggesting a partial-thickness delaminated tear; type IV, presence of a minor discontinuity in only 1 or 2 slices on both oblique coronal and sagittal images, suggesting a small full-thickness tear; and type V, presence of a major discontinuity observed in more than 2 slices on both oblique coronal and sagittal images.",100.0
1477,10.1016/j.ejvs.2012.02.003,Eligibility,"Exclusion criteria were as follows: combined aneurysmal-occlusive disease, impossible infrarenal clamping based on preoperative computed tomography (CT) scan, Fontaine IVb, age >80 years, creatinine >3.0 mg dl−1, severe pulmonary insufficiency (partial pressure of oxygen in the blood (PaO2) < 60 mmHg or partial pressure of carbon dioxide in the blood (PaCO2) > 50 mmHg on room air), severe cardiac dysfunction (myocardial infarction in past 6 months, ejection fraction <35% and severe aortic valve stenosis), previous aortic or major abdominal surgery, previous abdominal radiation therapy or severe pancreatitis, failed epidural anaesthesia or any contra-indication for epidural or general anaesthesia and patients not willing to sign informed consent.","Exclusion criteria were as follows: combined aneurysmal-occlusive disease, impossible infrarenal clamping based on preoperative computed tomography (CT) scan, Fontaine IVb, age >80 years, creatinine >3.0 mg dl−1, severe pulmonary insufficiency (partial pressure of oxygen in the blood (PaO2) < 60 mmHg or partial pressure of carbon dioxide in the blood (PaCO2) > 50 mmHg on room air), severe cardiac dysfunction (myocardial infarction in past 6 months, ejection fraction <35% and severe aortic valve stenosis), previous aortic or major abdominal surgery, previous abdominal radiation therapy or severe pancreatitis, failed epidural anaesthesia or any contra-indication for epidural or general anaesthesia and patients not willing to sign informed consent.",100.0
1477,10.1016/j.ejvs.2012.02.003,Eligibility,"Demographic data (including age, gender, weight and length) and cardiovascular risk factors (including diabetes mellitus (DM), atherosclerotic heart disease (ASHD), hypercholesterolaemia, hypertension and smoking) of all patients included were documented.","Demographic data (including age, gender, weight and length) and cardiovascular risk factors (including diabetes mellitus (DM), atherosclerotic heart disease (ASHD), hypercholesterolaemia, hypertension and smoking) of all patients included were documented.",100.0
1477,10.1016/j.ejvs.2012.02.003,Eligibility,Patients were followed up in the outpatient vascular surgery clinic at 2 weeks and 1 month postoperatively.,Patients were followed up in the outpatient vascular surgery clinic at 2 weeks and 1 month postoperatively.,100.0
1477,10.1016/j.ejvs.2012.02.003,Recruitment,"Between January 2007 and November 2009, 28 patients with severe aorto-iliac occlusive disease (TASC II C or D) were included.","Between January 2007 and November 2009, 28 patients with severe aorto-iliac occlusive disease (TASC II C or D) were included.",100.0
1477,10.1016/j.ejvs.2012.02.003,Recruitment,Patients were operated for a TASC II C lesion (five laparoscopically and four open surgical bypass). Nineteen patients underwent aorto-iliac surgery for a TASC II D lesion (nine laparoscopically and 10 open).,patients were operated for a TASC II C lesion (five laparoscopically and four open surgical bypass). Nineteen patients underwent aorto-iliac surgery for a TASC II D lesion (nine laparoscopically and 10 open,100.0
1477,10.1016/j.ejvs.2012.02.003,Recruitment,"However, if differences in postoperative course are obvious, at a certain level of experience it becomes difficult to justify randomisation. On the other hand, as long as there is no randomised trial it is difficult to document differences in morbidity and mortality with a high level of evidence and it becomes difficult to convince surgeons to invest in learning a technically demanding technique.","However, if differences in postoperative course are obvious, at a certain level of experience it becomes difficult to justify randomisation. On the other hand, as long as there is no randomised trial it is difficult to document differences in morbidity and mortality with a high level of evidence and it becomes difficult to convince surgeons to invest in learning a technically demanding technique.",100.0
1477,10.1016/j.ejvs.2012.02.003,Setting,"Nine procedures were performed at the community hospital (five laparoscopically, four open) and 19 procedures were performed at the university hospital (nine laparoscopically, 10 open).","Nine procedures were performed at the community hospital (five laparoscopically, four open) and 19 procedures were performed at the university hospital (nine laparoscopically, 10 open).",100.0
1477,10.1016/j.ejvs.2012.02.003,Setting,The protocol of this study was approved by the ethical committee of each centre.,The protocol of this study was approved by the ethical committee of each centre.,100.0
1477,10.1016/j.ejvs.2012.02.003,Organisation,For all patients there was a standardised protocol for anaesthesia and patient-controlled epidural anaesthesia (PCEA).,For all patients there was a standardised protocol for anaesthesia and patient-controlled epidural anaesthesia (PCEA).,100.0
1477,10.1016/j.ejvs.2012.02.003,Organisation,"Perioperative antibiotics, intravenous cefazolin or vancomycin for penicillin-allergic patients, were administered for 24 h.","Perioperative antibiotics, intravenous cefazolin or vancomycin for penicillin-allergic patients, were administered for 24 h.",100.0
1477,10.1016/j.ejvs.2012.02.003,Organisation,Patients were extubated at the end of the procedure. Routine postoperative monitoring in the post-anaesthetic recovery room was the same for all patients.,Patients were extubated at the end of the procedure. Routine postoperative monitoring in the post-anaesthetic recovery room was the same for all patients.,100.0
1477,10.1016/j.ejvs.2012.02.003,Flexibility (delivery),A standardised operative technique was used.,A standardised operative technique was used.,100.0
1477,10.1016/j.ejvs.2012.02.003,Flexibility (delivery),The type of aorto-prosthetic anastomosis (end-to-end or end-to-side) is decided based on the quality of the aorta as estimated on the preoperative CT scan.,The type of aorto-prosthetic anastomosis (end-to-end or end-to-side) is decided based on the quality of the aorta as estimated on the preoperative CT scan.,100.0
1477,10.1016/j.ejvs.2012.02.003,Flexibility (adherence),Patients were encouraged to move from the bed to the chair and walk around as soon as they were comfortable.,Patients were encouraged to move from the bed to the chair and walk around as soon as they were comfortable.,100.0
1477,10.1016/j.ejvs.2012.02.003,Flexibility (adherence),"Patients were discharged and sent home as soon as they were clinically stable, tolerating a regular diet, opened their bowels and were able to walk around.","Patients were discharged and sent home as soon as they were clinically stable, tolerating a regular diet, opened their bowels and were able to walk around.",100.0
1477,10.1016/j.ejvs.2012.02.003,Follow-up,Patients were followed up clinically twice daily or more frequently as needed during their hospitalisation until discharge.,patients were followed up clinically twice daily or more frequently as needed during their hospitalisation until discharge,100.0
1477,10.1016/j.ejvs.2012.02.003,Follow-up,Patients were followed up in the outpatient vascular surgery clinic at 2 weeks and 1 month postoperatively.,Patients were followed up in the outpatient vascular surgery clinic at 2 weeks and 1 month postoperatively.,100.0
1477,10.1016/j.ejvs.2012.02.003,Primary outcome,To investigate differences between open and laparoscopic aortobifemoral bypass surgery for aorto-iliac occlusive disease on postoperative morbidity and mortality.,To investigate differences between open and laparoscopic aortobifemoral bypass surgery for aorto-iliac occlusive disease on postoperative morbidity and mortality.,100.0
1477,10.1016/j.ejvs.2012.02.003,Primary analysis,Data were analysed on an intention-to-treat basis.,Data were analysed on an intention-to-treat basis.,100.0
1292,10.1097/sla.0000000000002894,Eligibility,"Exclusion criteria were contraindications for general anesthesia or laparoscopy, obstructed or strangulated inguinal hernias, and hernia recurrences.","Exclusion criteria were contraindications for general anesthesia or laparoscopy, obstructed or strangulated inguinal hernias, and hernia recurrences.",100.0
1292,10.1097/sla.0000000000002894,Eligibility,"Patients (aged over 18 yrs), with primary, bilateral inguinal hernias assessed by ultrasound were included.","Patients (aged over 18 yrs), with primary, bilateral inguinal hernias assessed by ultrasound were included.",100.0
1292,10.1097/sla.0000000000002894,Eligibility,Cases were randomized using a simple randomization with a computer program and divided into 2 groups according to the surgical approach elected by the computer program: TAPP or OL group.,Cases were randomized using a simple randomization with a computer program and divided into 2 groups according to the surgical approach elected by the computer program: TAPP or OL group.,100.0
1292,10.1097/sla.0000000000002894,Recruitment,This study was carried out in a private hospital in Madrid (Spain) at the General Surgery Department of Sanchinarro University Hospital recruiting patients from March 2013.,This study was carried out in a private hospital in Madrid (Spain) at the General Surgery Department of Sanchinarro University Hospital recruiting patients from March 2013.,100.0
1292,10.1097/sla.0000000000002894,Recruitment,Patients were transferred to the ward with all of them staying overnight.,Patients were transferred to the ward with all of them staying overnight.,100.0
1292,10.1097/sla.0000000000002894,Recruitment,The study was approved by the institutional ethical committee of the HM Hospitals group. All patients included were informed about the treatment and written informed consent was obtained.,The study was approved by the institutional ethical committee of the HM Hospitals group. All patients included were informed about the treatment and written informed consent was obtained.,100.0
1292,10.1097/sla.0000000000002894,Setting,This study was carried out in a private hospital in Madrid (Spain) at the General Surgery Department of Sanchinarro University Hospital recruiting patients from March 2013.,This study was carried out in a private hospital in Madrid (Spain) at the General Surgery Department of Sanchinarro University Hospital recruiting patients from March 2013.,100.0
1292,10.1097/sla.0000000000002894,Organisation,The same team of surgeons (4 senior consultant surgeons with a minimum of 2 years’ experience in both TAPP and OL techniques) and an anesthesiology team performed the operation.,The same team of surgeons (4 senior consultant surgeons with a minimum of 2 years’ experience in both TAPP and OL techniques) and an anesthesiology team performed the operation.,100.0
1292,10.1097/sla.0000000000002894,Organisation,All procedures were performed using the same surgical steps as follows.,All procedures were performed using the same surgical steps as follows.,100.0
1292,10.1097/sla.0000000000002894,Organisation,Patients were transferred to the ward with all of them staying overnight.,Patients were transferred to the ward with all of them staying overnight.,100.0
1292,10.1097/sla.0000000000002894,Flexibility (delivery),All procedures were performed using the same surgical steps as follows.,All procedures were performed using the same surgical steps as follows.,100.0
1292,10.1097/sla.0000000000002894,Flexibility (delivery),"Patients are allowed to resume their full activities after 10 days from surgery, except for physical exercise which was recommended to commence after 30 days from surgery.","Patients are allowed to resume their full activities after 10 days from surgery, except for physical exercise which was recommended to commence after 30 days from surgery.",100.0
1292,10.1097/sla.0000000000002894,Flexibility (adherence),"Patients are allowed to resume their full activities after 10 days from surgery, except for physical exercise which was recommended to commence after 30 days from surgery.","Patients are allowed to resume their full activities after 10 days from surgery, except for physical exercise which was recommended to commence after 30 days from surgery.",100.0
1292,10.1097/sla.0000000000002894,Follow-up,"During follow-up, there was a drop out of 6 patients (2 TAPP, 4 OL) and they have been excluded only from the cost-effectiveness analysis.","During follow-up, there was a drop out of 6 patients (2 TAPP, 4 OL) and they have been excluded only from the cost-effectiveness analysis.",100.0
1292,10.1097/sla.0000000000002894,Follow-up,A summary of costs is presented in Table 3.,A summary of costs is presented in Table 3.,100.0
1292,10.1097/sla.0000000000002894,Primary outcome,"The outcome parameters included surgical and postoperative costs, quality adjusted life years (QALY), and incremental cost per QALY gained or the incremental cost effectiveness ratio.","The outcome parameters included surgical and postoperative costs, quality adjusted life years (QALY), and incremental cost per QALY gained or the incremental cost effectiveness ratio.",100.0
1292,10.1097/sla.0000000000002894,Primary outcome,The mean QALYs at 1 year for TAPP (0.8094) was higher than that associated with OL (0.6765) (P = 0.018).,The mean QALYs at 1 year for TAPP (0.8094) was higher than that associated with OL (0.6765) (P = 0.018).,100.0
1292,10.1097/sla.0000000000002894,Primary analysis,"The estimated ICER for patients was 3696.10€ per QALY gained, in favor of TAPP.","The estimated ICER for patients was 3696.10€ per QALY gained, in favor of TAPP",100.0
1292,10.1097/sla.0000000000002894,Primary analysis,"In Monte Carlo simulations analysis, there was a 10.08% probability that TAPP is both less costly and more effective.","In Monte Carlo simulations analysis, there was a 10.08% probability that TAPP is both less costly and more effective.",100.0
1499,10.1097/sla.0000000000003449,Eligibility,This trial enrolled 400 female Stage 0–III breast cancer patients aged 18 years or older undergoing partial mastectomy.,This trial enrolled 400 female Stage 0–III breast cancer patients aged 18 years or older undergoing partial mastectomy.,100.0
1499,10.1097/sla.0000000000003449,Eligibility,"Exclusion criteria included excisional biopsy for diagnosis, prior attempt at partial mastectomy, bilateral breast cancer, and plan for intraoperative radiation therapy.","Exclusion criteria included excisional biopsy for diagnosis, prior attempt at partial mastectomy, bilateral breast cancer, and plan for intraoperative radiation therapy.",100.0
1499,10.1097/sla.0000000000003449,Eligibility,"Patients were screened for eligibility at each site, and written informed consent was obtained.","Patients were screened for eligibility at each site, and written informed consent was obtained.",100.0
1499,10.1097/sla.0000000000003449,Recruitment,"Between July 28, 2016 and April 13, 2018, 400 patients were enrolled in this trial.","Between July 28, 2016 and April 13, 2018, 400 patients were enrolled in this trial.",100.0
1499,10.1097/sla.0000000000003449,Recruitment,The study was registered at ClinicalTrials.gov (NCT02772731)., The trial was registered at ClinicalTrials.gov (NCT0277273,93.22033898305084
1499,10.1097/sla.0000000000003449,Setting,In this multicenter randomized controlled trial occurring in 9 centers across the United States...,"
In this multicenter randomized controlled trial occurring in 9 centers across the United State",100.0
1499,10.1097/sla.0000000000003449,Setting,Nine centers from across the United States (Table 1) participated in this prospective randomized controlled trial.,Nine centers from across the United States (Table 1) participated in this prospective randomized controlled trial.,100.0
1499,10.1097/sla.0000000000003449,Organisation,The study protocol is attached in the Appendix here.,The study protocol is attached in the Appendix here.,100.0
1499,10.1097/sla.0000000000003449,Organisation,The study was monitored biannually by the Yale Cancer Center Data Safety Monitoring Committee.,The study was monitored biannually by the Yale Cancer Center Data Safety Monitoring Committee.,100.0
1499,10.1097/sla.0000000000003449,Flexibility (delivery),"Surgeons were instructed to perform partial mastectomy according to their usual practice, including excision of selective margins based on intraoperative imaging and/or their own gross evaluation.","Surgeons were instructed to perform partial mastectomy according to their usual practice, including excision of selective margins based on intraoperative imaging and/or their own gross evaluation.",100.0
1499,10.1097/sla.0000000000003449,Flexibility (delivery),"Once the surgeon completed the partial mastectomy, a phone call was placed to the coordinating center at Yale and the patient's randomization group was revealed to the surgical team."," Once the surgeon completed the partial mastectomy, a phone call was placed to the coordinating center at Yale and the patient's randomization group was revealed to the surgical tea",100.0
1499,10.1097/sla.0000000000003449,Flexibility (adherence),Re-excision was left to the discretion of the surgeon.,Re-excision was left to the discretion of the surgeon.,100.0
1499,10.1097/sla.0000000000003449,Flexibility (adherence),"Of the 91 patients who had a positive final margin, 61 (67.0%) underwent a re-excision. Re-excision was left to the discretion of the surgeon.","Of the 91 patients who had a positive final margin, 61 (67.0%) underwent a re-excision. Re-excision was left to the discretion of the surgeon.",100.0
1499,10.1097/sla.0000000000003449,Follow-up,"Median follow-up time was 13 months (range, 4–31).","Median follow-up time was 13 months (range, 4–31).",100.0
1499,10.1097/sla.0000000000003449,Follow-up,"Cosmetic outcome and quality of life (each measured at 1- and 5-yrs), and 5-year local recurrence rate will be reported in due course.","Cosmetic outcome and quality of life (each measured at 1- and 5-yrs), and 5-year local recurrence rate will be reported in due course.",100.0
1499,10.1097/sla.0000000000003449,Primary outcome,Primary outcome measures were positive margin and re-excision rates.,Primary outcome measures were positive margin and re-excision rates.,100.0
1499,10.1097/sla.0000000000003449,Primary outcome,Resection of CSM significantly reduces positive margin and re-excision rates in patients undergoing PM.,Resection of CSM significantly reduces positive margin and re-excision rates in patients undergoing PM.,100.0
1499,10.1097/sla.0000000000003449,Primary analysis,Group comparisons were made using Fisher exact or chi square tests for categorical variables and Mann–Whitney U tests for continuous variables.,Group comparisons were made using Fisher exact or chi square tests for categorical variables and Mann–Whitney U tests for continuous variables.,100.0
1499,10.1097/sla.0000000000003449,Primary analysis,IBM SPSS Statistics version 24.0 was used for statistical analysis.,IBM SPSS Statistics version 24.0 was used for statistical analysis.,100.0
1361,10.1097/sla.0b013e3181d96c32,Eligibility,"Adults presenting with primary or recurrent inguinal hernias, uni- or bilateral, with an indication for elective correction, were eligible for randomization.","Adults presenting with primary or recurrent inguinal hernias, uni- or bilateral, with an indication for elective correction, were eligible for randomization.",100.0
1361,10.1097/sla.0b013e3181d96c32,Eligibility,"Exclusion criteria were scrotal hernia, pregnancy, and communicative or cognitive limitation that prevented informed consent.","Exclusion criteria were scrotal hernia, pregnancy, and communicative or cognitive limitation that prevented informed consent.",100.0
1361,10.1097/sla.0b013e3181d96c32,Eligibility,"A medical history of prostatectomy, pfannenstiel incision, preperitoneal procedure, or abdominal bladder operation were other reasons for exclusion.","A medical history of prostatectomy, pfannenstiel incision, preperitoneal procedure, or abdominal bladder operation were other reasons for exclusion.",100.0
1361,10.1097/sla.0b013e3181d96c32,Recruitment,"Between August 2000 and March 2004, 722 patients consented to randomization.","
Between August 2000 and March 2004, 722 patients consented to randomizatio",100.0
1361,10.1097/sla.0b013e3181d96c32,Recruitment,"Randomization for TEP or Lichtenstein was carried out by telephone or fax at the outpatient clinic, by the central study coordinator, according to a balanced and stratified computer-generated list.","Randomization for TEP or Lichtenstein was carried out by telephone or fax at the outpatient clinic, by the central study coordinator, according to a balanced and stratified computer-generated list.",100.0
1361,10.1097/sla.0b013e3181d96c32,Recruitment,The trial is registered at www.clinicaltrials.gov with number NCT00788554.,The trial is registered at www.clinicaltrials.gov with number NCT00788554.,100.0
1361,10.1097/sla.0b013e3181d96c32,Setting,"Six hospitals, including 1 university hospital in the Netherlands participated in the “LEVEL”-trial.","Six hospitals, including 1 university hospital in the Netherlands participated in the “LEVEL”-trial.",100.0
1361,10.1097/sla.0b013e3181d96c32,Organisation,Surgeons and residents were experienced with both procedures or were supervised by an experienced surgeon.,Surgeons and residents were experienced with both procedures or were supervised by an experienced surgeon.,100.0
1361,10.1097/sla.0b013e3181d96c32,Organisation,"For TEP, a surgeon who previously performed a minimum of 100 laparoscopic interventions and a minimum of 30 endoscopic corrections of inguinal hernias had to be present in the operating room throughout the whole procedure.","For TEP, a surgeon who previously performed a minimum of 100 laparoscopic interventions and a minimum of 30 endoscopic corrections of inguinal hernias had to be present in the operating room throughout the whole procedure.",100.0
1361,10.1097/sla.0b013e3181d96c32,Organisation,Use of prophylactic antibiotics was up to the surgeon and reported.,Use of prophylactic antibiotics was up to the surgeon and reported.,100.0
1361,10.1097/sla.0b013e3181d96c32,Flexibility (delivery),Both procedures were performed under standardized techniques.,Both procedures were performed under standardized techniques.,100.0
1361,10.1097/sla.0b013e3181d96c32,Flexibility (delivery),"Instructions were given to all patients, to resume normal daily activities and return to work as soon as possible, irrespective of the operative method.","Instructions were given to all patients, to resume normal daily activities and return to work as soon as possible, irrespective of the operative method.",100.0
1361,10.1097/sla.0b013e3181d96c32,Flexibility (adherence),Neither identification nor nerve sparing surgery influenced chronic pain., Neither identification nor nerve sparing surgery influenced chronic pai,100.0
1361,10.1097/sla.0b013e3181d96c32,Follow-up,Follow-up after 6 weeks was completed in 89% (568) and 1 year in 77% (495).,Follow-up after 6 weeks was completed in 89% (568) and 1 year in 77% (495).,100.0
1361,10.1097/sla.0b013e3181d96c32,Follow-up,One-year follow-up was completed in 82% in the TEP group and 73% in the Lichtenstein group.,One-year follow-up was completed in 82% in the TEP group and 73% in the Lichtenstein group.,100.0
1361,10.1097/sla.0b013e3181d96c32,Primary outcome,"Primary outcomes were postoperative pain, length of hospital stay, period until complete recovery, and quality of life (QOL).","Primary outcomes were postoperative pain, length of hospital stay, period until complete recovery, and quality of life (QOL).",100.0
1361,10.1097/sla.0b013e3181d96c32,Primary outcome,"Recurrences, operating time, complications, chronic pain, and costs were secondary endpoints.","Recurrences, operating time, complications, chronic pain, and costs were secondary endpoints.",100.0
1361,10.1097/sla.0b013e3181d96c32,Primary analysis,Primary analysis was performed on an intention to treat basis.,Primary analysis was performed on an intention to treat basis.,100.0
1493,10.1056/nejmoa1906190,Eligibility,We randomly assigned 1495 patients who were 50 years of age or older and had a displaced femoral neck fracture to undergo either total hip arthroplasty or hemiarthroplasty.,We randomly assigned 1495 patients who were 50 years of age or older and had a displaced femoral neck fracture to undergo either total hip arthroplasty or hemiarthroplasty.,100.0
1493,10.1056/nejmoa1906190,Eligibility,All enrolled patients had been able to ambulate without the assistance of another person before the fracture occurred.,All enrolled patients had been able to ambulate without the assistance of another person before the fracture occurred.,100.0
1493,10.1056/nejmoa1906190,Recruitment,"We enrolled patients at 80 participating sites in Canada, the United States, Spain, the United Kingdom, the Netherlands, Norway, Finland, Australia, New Zealand, and South Africa.","We enrolled patients at 80 participating sites in Canada, the United States, Spain, the United Kingdom, the Netherlands, Norway, Finland, Australia, New Zealand, and South Africa.",100.0
1493,10.1056/nejmoa1906190,Setting,The trial was conducted in 80 centers in 10 countries.,The trial was conducted in 80 centers in 10 countries.,100.0
1493,10.1056/nejmoa1906190,Organisation,Nearly all participating surgeons (97.8%) met thresholds for surgical expertise.,Nearly all participating surgeons (97.8%) met thresholds for surgical expertise.,100.0
1493,10.1056/nejmoa1906190,Follow-up,"Over 24 months, the functional assessment tests and quality-of-life questionnaires were completed by 943 to 1141 patients (depending on the test) at one or more follow-up visits.","Over 24 months, the functional assessment tests and quality-of-life questionnaires were completed by 943 to 1141 patients (depending on the test) at one or more follow-up visits",100.0
1493,10.1056/nejmoa1906190,Primary outcome,The primary end point was any unplanned secondary hip procedure within 24 months after the initial surgery.,The primary end point was any unplanned secondary hip procedure within 24 months after the initial surgery.,100.0
1493,10.1056/nejmoa1906190,Primary analysis,Analyses included patients in the groups to which they had been randomly assigned.,Analyses included patients in the groups to which they had been randomly assigned.,100.0
1302,10.1097/sla.0000000000002229,Eligibility,We included patients between ages of 21 and 80 years with histological diagnosis of gastric adenocarcinoma who underwent radical DG with curative intent.,We included patients between ages of 21 and 80 years with histological diagnosis of gastric adenocarcinoma who underwent radical DG with curative intent.,100.0
1302,10.1097/sla.0000000000002229,Eligibility,"Patients who had previous gastrectomy, stomach, or small bowel surgery precluding construction of either form of anastomosis, radiological evidence of carcinomatosis, or who were admitted for emergency gastrectomy for complications related to the tumor, such as perforation, bleeding, and obstruction, were excluded.","Patients who had previous gastrectomy, stomach, or small bowel surgery precluding construction of either form of anastomosis, radiological evidence of carcinomatosis, or who were admitted for emergency gastrectomy for complications related to the tumor, such as perforation, bleeding, and obstruction, were excluded.",100.0
1302,10.1097/sla.0000000000002229,Recruitment,"Between October 2008 and October 2014, a total of 164 patients were recruited for the trial.","Between October 2008 and October 2014, a total of 164 patients were recruited for the trial.",100.0
1302,10.1097/sla.0000000000002229,Setting,This is a multicenter prospective RCT conducted at specialized Upper Gastrointestinal (UGI) Surgery units at 4 tertiary hospitals in Singapore and Hong Kong.,This is a multicenter prospective RCT conducted at specialized Upper Gastrointestinal (UGI) Surgery units at 4 tertiary hospitals in Singapore and Hong Kong.,100.0
1302,10.1097/sla.0000000000002229,Organisation,All operations were performed by UGI surgeons who are specialized in gastric cancer surgery.,All operations were performed by UGI surgeons who are specialized in gastric cancer surgery.,100.0
1302,10.1097/sla.0000000000002229,Flexibility (delivery),The techniques of reconstruction were standardized throughout the participating institutions., The techniques of reconstruction were standardized throughout the participating institution,100.0
1302,10.1097/sla.0000000000002229,Follow-up,Study participants were reviewed at 6 months and 1 year postoperatively.,Study participants were reviewed at 6 months and 1 year postoperatively.,100.0
1302,10.1097/sla.0000000000002229,Primary outcome,The primary outcome measure of the study was the GI Symptoms Score in patients who underwent R-Y and B-II reconstruction after 1 year.,The primary outcome measure of the study was the GI Symptoms Score in patients who underwent R-Y and B-II reconstruction after 1 year.,100.0
1302,10.1097/sla.0000000000002229,Primary analysis,The analysis was performed on the basis of the principle of intention-to-treat.,The analysis was performed on the basis of the principle of intention-to-treat.,100.0
1352,10.1097/sla.0b013e3182765fcf,Eligibility,"Consecutive patients admitted for suspected acute appendicitis, aged between 18 and 75 years, were recruited. We included patients with a history of right lower quadrant pain or periumbilical pain migrating to the right lower quadrant, presence of right lower quadrant guarding, tenderness upon physical examination, and fever of more than 38°C and/or white cell counts more than 10 × 103 cells per mL.","Consecutive patients admitted for suspected acute appendicitis, aged between 18 and 75 years, were recruited. We included patients with a history of right lower quadrant pain or periumbilical pain migrating to the right lower quadrant, presence of right lower quadrant guarding, tenderness upon physical examination, and fever of more than 38°C and/or white cell counts more than 10 × 103 cells per mL.",100.0
1352,10.1097/sla.0b013e3182765fcf,Eligibility,"The exclusion criteria were as follows: diagnosis of appendicitis was not clinically established (symptoms attributable to urinary or gynecological problems), symptoms of more than 5 days, and/or a palpable mass in the right lower quadrant suggesting an appendiceal mass. Additional patients with the following conditions were also excluded: history of cirrhosis and coagulation disorders, generalized peritonitis, shock upon admission, previous abdominal surgery, ascites, suspected or proven malignancy, contraindication to general anesthesia (severe cardiac and/or pulmonary disease), inability to give informed consent, and pregnancy.","The exclusion criteria were as follows: diagnosis of appendicitis was not clinically established (symptoms attributable to urinary or gynecological problems), symptoms of more than 5 days, and/or a palpable mass in the right lower quadrant suggesting an appendiceal mass. Additional patients with the following conditions were also excluded: history of cirrhosis and coagulation disorders, generalized peritonitis, shock upon admission, previous abdominal surgery, ascites, suspected or proven malignancy, contraindication to general anesthesia (severe cardiac and/or pulmonary disease), inability to give informed consent, and pregnancy.",100.0
1352,10.1097/sla.0b013e3182765fcf,Recruitment,"Between October 2009 and March 2011, consecutive patients admitted with clinical or radiological evidence of appendicitis were randomly assigned to receive either LESS or TPLA.","Between October 2009 and March 2011, consecutive patients admitted with clinical or radiological evidence of appendicitis were randomly assigned to receive either LESS or TPLA.",100.0
1352,10.1097/sla.0b013e3182765fcf,Recruitment,The patients were randomized after surgery was offered. They were randomly allocated to LESS appendectomy (group A) or TPLA (group B) by opening sealed envelopes containing a computer-generated code in blocks of 10.,The patients were randomized after surgery was offered. They were randomly allocated to LESS appendectomy (group A) or TPLA (group B) by opening sealed envelopes containing a computer-generated code in blocks of 10.,100.0
1352,10.1097/sla.0b013e3182765fcf,Setting,"The study was performed between October 2009 and March 2011 in the Prince of Wales Hospital (University affiliated) and the North District Hospital. Together, the 2 hospitals provide government-supported services to the Eastern New Territories' region in Hong Kong, which is comprised of a population of approximately 1 million people.","The study was performed between October 2009 and March 2011 in the Prince of Wales Hospital (University affiliated) and the North District Hospital. Together, the 2 hospitals provide government-supported services to the Eastern New Territories' region in Hong Kong, which is comprised of a population of approximately 1 million people.",100.0
1352,10.1097/sla.0b013e3182765fcf,Organisation,All procedures were performed or supervised by specialist surgeons with experience of more than 20 LESS appendectomies. They were also proficient with advanced laparoscopic surgical techniques and had experience of more than 100 laparoscopic procedures in their respective subspecialties.,All procedures were performed or supervised by specialist surgeons with experience of more than 20 LESS appendectomies. They were also proficient with advanced laparoscopic surgical techniques and had experience of more than 100 laparoscopic procedures in their respective subspecialties.,100.0
1352,10.1097/sla.0b013e3182765fcf,Organisation,"Four designated surgeons performed all the procedures in Prince of Wales Hospital, whereas the operations in North District Hospital were performed by 2 designated surgeons.","Four designated surgeons performed all the procedures in Prince of Wales Hospital, whereas the operations in North District Hospital were performed by 2 designated surgeons.",100.0
1352,10.1097/sla.0b013e3182765fcf,Flexibility (delivery),Two 5-mm ports and one 10-mm port were inserted through a 13-mm transumbilical incision via multiple fascial incisions.,"
Two 5-mm ports and one 10-mm port were inserted through a 13-mm transumbilical incision via multiple fascial incision",100.0
1352,10.1097/sla.0b013e3182765fcf,Flexibility (delivery),"Conversion would be performed for the following reasons: unclear anatomy, compromised safety of dissection, complications including bleeding or adjacent organ injury, or severe contamination. Conversion would be first to TPLA followed by open appendectomy if the 3-port technique was unable to adequately address the aforementioned problems.","Conversion would be performed for the following reasons: unclear anatomy, compromised safety of dissection, complications including bleeding or adjacent organ injury, or severe contamination. Conversion would be first to TPLA followed by open appendectomy if the 3-port technique was unable to adequately address the aforementioned problems.",100.0
1352,10.1097/sla.0b013e3182765fcf,Follow-up,"Patients were discharged when regular diet was well tolerated, they were afebrile for 24 hours and white cell counts were at a decreasing trend (20% less than admission values in patients with abnormal values). They were then required to follow-up at 2 weeks for reassessment.","Patients were discharged when regular diet was well tolerated, they were afebrile for 24 hours and white cell counts were at a decreasing trend (20% less than admission values in patients with abnormal values). They were then required to follow-up at 2 weeks for reassessment.",100.0
1352,10.1097/sla.0b013e3182765fcf,Primary outcome,The main outcome measurement was overall pain score.,The main outcome measurement was overall pain score.,100.0
1352,10.1097/sla.0b013e3182765fcf,Primary analysis,All outcomes were analyzed according to the intention-to-treat principle.,All outcomes were analyzed according to the intention-to-treat principle.,100.0
1472,10.1016/j.ejvs.2007.11.024,Eligibility,Hundred and nine subjects were randomized 2:1 to treatment or control.,Hundred and nine subjects were randomized 2:1 to treatment or control.,100.0
1472,10.1016/j.ejvs.2007.11.024,Eligibility,Eligible participants were included if they satisfied all inclusion and exclusion criteria.,Eligible participants were included if they satisfied all inclusion and exclusion criteria,100.0
1472,10.1016/j.ejvs.2007.11.024,Eligibility,"Based on the length of the study and history of vascular disease, at least 104 subjects were planned to be enrolled.","sed upon the length of the study and history of vascular disease, at least 104 subjects were planned to be enrolled",98.26086956521739
1472,10.1016/j.ejvs.2007.11.024,Recruitment,"This study was conducted at nine investigational sites in Hungary, The Netherlands and The Netherlands Antilles.","This study was conducted at nine investigational sites in Hungary, The Netherlands and The Netherlands Antilles.",100.0
1472,10.1016/j.ejvs.2007.11.024,Recruitment,Study subjects provided written informed consent prior to their enrollment into this study.,Study subjects provided written informed consent prior to their enrollment into this study.,100.0
1472,10.1016/j.ejvs.2007.11.024,Setting,"This study was conducted at nine investigational sites in Hungary, The Netherlands and The Netherlands Antilles.","This study was conducted at nine investigational sites in Hungary, The Netherlands and The Netherlands Antilles.",100.0
1472,10.1016/j.ejvs.2007.11.024,Organisation,"This study was conducted at nine investigational sites in Hungary, The Netherlands and The Netherlands Antilles.","This study was conducted at nine investigational sites in Hungary, The Netherlands and The Netherlands Antilles.",100.0
1472,10.1016/j.ejvs.2007.11.024,Organisation,"All aspects of the study were governed by the applicable sections of the International Conference on Harmonisation Guidelines for Good Clinical Practice (E6), EN ISO 14155 Clinical Investigation of Medical Devices for Human Subjects, the Declaration of Helsinki of 1964 and its subsequent revisions, and by the standard operating procedures of all reviewing ethics committees, contract research organizations, and the study sponsor.","All aspects of the study were governed by the applicable sections of the International Conference on Harmonisation Guidelines for Good Clinical Practice (E6), EN ISO 14155 Clinical Investigation of Medical Devices for Human Subjects, the Declaration of Helsinki of 1964 and its subsequent revisions, and by the standard operating procedures of all reviewing ethics committees, contract research organizations, and the study sponsor.",100.0
1472,10.1016/j.ejvs.2007.11.024,Flexibility (delivery),"If the subject was randomized to the treatment group, the backing layer was first removed from the wrap, and then the wrap was placed around the distal end of the anastomosis.","If the subject was randomized to the treatment group, the backing layer was first removed from the wrap, and then the wrap was placed around the distal end of the anastomosis",100.0
1472,10.1016/j.ejvs.2007.11.024,Flexibility (adherence),No adverse events were considered related to the use of the paclitaxel-eluting wrap.,No adverse events were considered related to the use of the paclitaxel-eluting wrap,100.0
1472,10.1016/j.ejvs.2007.11.024,Follow-up,"Safety, clinical performance and efficacy evaluations, conducted on the day the subject was discharged from the hospital, were: a physical examination (affected limb assessment), concomitant medications query, adverse events (AEs) reporting, and ultrasound measurements, performed at some sites.","Safety, clinical performance and efficacy evaluations, conducted on the day the subject was discharged from the hospital, were: a physical examination (affected limb assessment), concomitant medications query, adverse events (AEs) reporting, and ultrasound measurements, performed at some sites.",100.0
1472,10.1016/j.ejvs.2007.11.024,Follow-up,"These assessments were repeated during subject follow-up visits at Week 6 and at Months 3, 6, 12, and 18.","These assessments were repeated during subject follow-up visits at Week 6 and at Months 3, 6, 12, and 18.",100.0
1472,10.1016/j.ejvs.2007.11.024,Follow-up,"At Month 24, safety and performance evaluations included the above-listed assessments and clinical laboratory tests.","At Month 24, safety and performance evaluations included the above-listed assessments and clinical laboratory tests.",100.0
1472,10.1016/j.ejvs.2007.11.024,Primary outcome,The paclitaxel-eluting wrap maintained the mean diameter of the distal anastomosis throughout the 24 months compared with a decreasing mean diameter in controls; the difference was statistically significant at 2 years.,The paclitaxel-eluting wrap maintained the mean diameter of the distal anastomosis throughout the 24 months compared with a decreasing mean diameter in controls; the difference was statistically significant at 2 years.,100.0
1472,10.1016/j.ejvs.2007.11.024,Primary analysis,"Descriptive statistics were performed on all demographic, safety, and performance variables.","Descriptive statistics were performed on all demographic, safety, and performance variables.",100.0
1472,10.1016/j.ejvs.2007.11.024,Primary analysis,No formal statistical tests were planned or performed on any of the demographic or safety variables; this study was not designed to detect quantitative differences in these measures.,No formal statistical tests were planned or performed on any of the demographic or safety variables; this study was not designed to detect quantitative differences in these measures.,100.0
1225,10.1016/j.arthro.2011.01.015,Eligibility,"Exclusion criteria were any concomitant ligament or meniscus injury or previous surgery, evidence of chondral lesion higher than grade 2, and any damage to the contralateral knee.","Exclusion criteria were any concomitant ligament or meniscus injury or previous surgery, evidence of chondral lesion higher than grade 2, and any damage to the contralateral knee.",100.0
1225,10.1016/j.arthro.2011.01.015,Eligibility,Intraoperative findings and other reasons led to the exclusion of 9 further patients until the 1-year follow-up.,Intraoperative findings and other reasons led to the exclusion of 9 further patients until the 1-year follow-up.,100.0
1225,10.1016/j.arthro.2011.01.015,Eligibility,Patients with a rerupture after ACL reconstruction were excluded from the study.,Patients with a rerupture after ACL reconstruction were excluded from the study.,100.0
1225,10.1016/j.arthro.2011.01.015,Eligibility,All patients were operated on between October 1998 and September 1999 by the senior author.,All patients were operated on between October 1998 and September 1999 by the senior author.,100.0
1225,10.1016/j.arthro.2011.01.015,Eligibility,The mean time between injury and surgery was 78.7 days in the BPT group and 77.6 days in the HT group.,The mean time between injury and surgery was 78.7 days in the BPT group and 77.6 days in the HT group.,100.0
1225,10.1016/j.arthro.2011.01.015,Eligibility,"All patients were operated by the same surgeon, who is well experienced in both techniques.","All patients were operated by the same surgeon, who is well experienced in both techniques.",100.0
1225,10.1016/j.arthro.2011.01.015,Eligibility,The operation techniques were comparable.,The operation techniques were comparable.,100.0
1225,10.1016/j.arthro.2011.01.015,Eligibility,All patients received the same postoperative management and were clinically examined by 2 independent examiners.,All patients received the same postoperative management and were clinically examined by 2 independent examiners.,100.0
1225,10.1016/j.arthro.2011.01.015,Eligibility,An arthroscopic-assisted technique was used for both grafts.,An arthroscopic-assisted technique was used for both grafts,100.0
1225,10.1016/j.arthro.2011.01.015,Eligibility,No significant difference in hamstring and quadriceps strength was measured in our study.,No significant difference in hamstring and quadriceps strength was measured in our study.,100.0
1225,10.1016/j.arthro.2011.01.015,Eligibility,"At a mean follow-up of 8.8 years (SD, 0.55 years; range, 7.41 to 10 years), 54 patients were examined.","At a mean follow-up of 8.8 years (SD, 0.55 years; range, 7.41 to 10 years), 54 patients were examined",100.0
1225,10.1016/j.arthro.2011.01.015,Eligibility,The significant difference between BPT and HT observed at 1-year follow-up in the Lysholm score was not seen 9 years after surgery.,The significant difference between BPT and HT observed at 1-year follow-up in the Lysholm score was not seen 9 years after surgery,100.0
1225,10.1016/j.arthro.2011.01.015,Eligibility,All patients were assessed by 2 independent examiners 9 years postoperatively.,All patients were assessed by 2 independent examiners 9 years postoperatively.,100.0
1679,10.1111/jjns.12160,Eligibility,"The inclusion criteria were: (i) aged ≥18 years; (ii) diagnosed with coronary heart disease and admitted for the first time; (iii) lived in the central districts of Chengdu; (iv) returned to the home residence, not long-term care facilities, after discharge; (v) could be contacted by mobile phone after discharge; and (vi) agreed to participate in the study.","The inclusion criteria were: (i) aged ≥18 years; (ii) diagnosed with coronary heart disease and admitted for the first time; (iii) lived in the central districts of Chengdu; (iv) returned to the home residence, not long-term care facilities, after discharge; (v) could be contacted by mobile phone after discharge; and (vi) agreed to participate in the study.",100.0
1679,10.1111/jjns.12160,Eligibility,"In total, 323 patients were contacted by the hospital nurse in the department of cardiology. As a result, 61 patients did not meet the inclusion criteria and 18 patients refused to participate in the study due to various reasons, five patients were excluded for dementia and three patients were excluded as they were not able to communicate effectively. In total, 236 patients were randomized to the study (n = 118) or the control (n = 118) group.","In total, 323 patients were contacted by the hospital nurse in the department of cardiology. As a result, 61 patients did not meet the inclusion criteria and 18 patients refused to participate in the study due to various reasons, five patients were excluded for dementia and three patients were excluded as they were not able to communicate effectively. In total, 236 patients were randomized to the study (n = 118) or the control (n = 118) group.",100.0
1679,10.1111/jjns.12160,Eligibility,"Patients in a general tertiary-level hospital in Chengdu, China, were recruited.","Patients in a general tertiary-level hospital in Chengdu, China, were recruited.",100.0
1679,10.1111/jjns.12160,Eligibility,"The hospital–community partnership transitional program was delivered by the combination of a hospital cardiologist and a hospital nurse, as well as a family physician and a home nurse in each community healthcare center to which each patient belonged.","The hospital–community partnership transitional program was delivered by the combination of a hospital cardiologist and a hospital nurse, as well as a family physician and a home nurse in each community healthcare center to which each patient belonged.",100.0
1679,10.1111/jjns.12160,Eligibility,"The program took reference to the Project BOOST (Better Outcomes for Older adults through Safe Transitions) (Society of Hospital Medicine, 2013). The five core principles that are central to the Project BOOST are: (i) patient centeredness: the project's focus is on the needs, abilities, and desires of the patients and their families or caregivers; (ii) patient and family or caregiver empowerment: hospital care teams address the patients' postdischarge needs and empower the patients and their families or caregivers to manage them; (iii) reduce the risk for harm after discharge: the healthcare teams conduct a follow-up phone call after discharge or an expedited follow-up appointment; (iv) team-oriented: successful transition requires collaboration among the nurses, case managers, physicians, patients, and their families or caregivers; (v) bridging the care transition gap: the hospital care teams interact with the after-care providers, patients, and their families or caregivers to ensure access and follow-up in order to help the patients to address any issue or question that arises after discharge.","The program took reference to the Project BOOST (Better Outcomes for Older adults through Safe Transitions) (Society of Hospital Medicine, 2013). The five core principles that are central to the Project BOOST are: (i) patient centeredness: the project's focus is on the needs, abilities, and desires of the patients and their families or caregivers; (ii) patient and family or caregiver empowerment: hospital care teams address the patients' postdischarge needs and empower the patients and their families or caregivers to manage them; (iii) reduce the risk for harm after discharge: the healthcare teams conduct a follow-up phone call after discharge or an expedited follow-up appointment; (iv) team-oriented: successful transition requires collaboration among the nurses, case managers, physicians, patients, and their families or caregivers; (v) bridging the care transition gap: the hospital care teams interact with the after-care providers, patients, and their families or caregivers to ensure access and follow-up in order to help the patients to address any issue or question that arises after discharge.",100.0
1679,10.1111/jjns.12160,Eligibility,"There was no significant difference in the medication adherence scores in the study group and the control group at the baseline (5.92 vs 5.81; t = 0.99, P = 0.319) (Table 3). Nevertheless, significant differences were noted both at O1 (6.86 vs 6.32; t = 5.66, P < 0.001) and O2 (6.77 vs 6.46; t = 3.50, P < 0.001).","There was no significant difference in the medication adherence scores in the study group and the control group at the baseline (5.92 vs 5.81; t = 0.99, P = 0.319) (Table 3). Nevertheless, significant differences were noted both at O1 (6.86 vs 6.32; t = 5.66, P < 0.001) and O2 (6.77 vs 6.46; t = 3.50, P < 0.001).",100.0
1679,10.1111/jjns.12160,Eligibility,"The data were collected at the baseline, 30 days (O1), and 90 days (O2) after discharge.","The data were collected at the baseline, 30 days (O1), and 90 days (O2) after discharge.",100.0
1679,10.1111/jjns.12160,Eligibility,The primary outcomes were the 30 and 90 day readmission rates after discharge.,The primary outcomes were the 30 and 90 day readmission rates after discharge.,100.0
1679,10.1111/jjns.12160,Eligibility,The trial was registered on the Chinese Clinical Trial Registry.,The trial was registered on the Chinese Clinical Trial Registry.,100.0
1524,10.1016/j.arthro.2019.05.026,Eligibility,"The inclusion criteria were patients with pain and full-thickness, medium-sized (1- to 3-cm) supraspinatus tears, confirmed with arthroscopy during the operative procedure, after unsuccessful conservative treatment (consisting of anti-inflammatory medications, physical therapy, and activity modification) for a minimum of 3 months.","The inclusion criteria were patients with pain and full-thickness, medium-sized (1- to 3-cm) supraspinatus tears, confirmed with arthroscopy during the operative procedure, after unsuccessful conservative treatment (consisting of anti-inflammatory medications, physical therapy, and activity modification) for a minimum of 3 months.",100.0
1524,10.1016/j.arthro.2019.05.026,Recruitment,"All patients were evaluated preoperatively and postoperatively (at 12 and 24 months) using the modified University of California, Los Angeles scoring system; active range of motion (flexion and external rotation); and a visual analog scale for pain.","All patients were evaluated preoperatively and postoperatively (at 12 and 24 months) using the modified University of California, Los Angeles scoring system; active range of motion (flexion and external rotation); and a visual analog scale for pain.",100.0
1524,10.1016/j.arthro.2019.05.026,Setting,"This study was approved by the institutional review board, and all patients provided informed consent. All surgical procedures were performed by the author (K.Y.).","This study was approved by the institutional review board, and all patients provided informed consent. All surgical procedures were performed by the author (K.Y.).",100.0
1524,10.1016/j.arthro.2019.05.026,Organisation,"The repair procedure (medially based single-row or suture bridge repair) was randomized after preparation of the footprint (including arthroscopic subacromial decompression, mobilization of the torn rotator cuff, debridement, and microfracture on the footprint, with or without tenotomy or tenodesis of the long head of the biceps tendon, if indicated) by opening a sealed envelope.","The repair procedure (medially based single-row or suture bridge repair) was randomized after preparation of the footprint (including arthroscopic subacromial decompression, mobilization of the torn rotator cuff, debridement, and microfracture on the footprint, with or without tenotomy or tenodesis of the long head of the biceps tendon, if indicated) by opening a sealed envelope.",100.0
1524,10.1016/j.arthro.2019.05.026,Follow-up,"The mean follow-up duration was 28.6 ± 3 months (range, 24-32 months).","The mean follow-up duration was 28.6 ± 3 months (range, 24-32 months).",100.0
1524,10.1016/j.arthro.2019.05.026,Primary outcome,This study did not show any significant differences in the clinical outcomes and cuff integrity between the 2 treatment groups at final follow-up.,This study did not show any significant differences in the clinical outcomes and cuff integrity between the 2 treatment groups at final follow-up,100.0
1760,pmid:25811824,Eligibility,"We enrolled participants who were 40 years or older, had diabetes mellitus or atherosclerotic cardiovascular disease, and were suboptimally adherent.","We enrolled participants who were 40 years or older, had diabetes mellitus or atherosclerotic cardiovascular disease, and were suboptimally adherent.",100.0
1760,pmid:25811824,Eligibility,"We excluded only individuals with medical conditions that might contraindicate the use of these medications, such as medication allergies, liver failure, cirrhosis, rhabdomyolysis, end-stage renal disease, chronic kidney disease.","We excluded only individuals with medical conditions that might contraindicate the use of these medications, such as medication allergies, liver failure, cirrhosis, rhabdomyolysis, end-stage renal disease, chronic kidney disease",100.0
1760,pmid:25811824,Recruitment,"We randomly selected 25,323 for study inclusion and randomized those people into one of the main study arms (n = 21,752) or to one of the 2 ancillary treatment arms (n = 3571).","we randomly selected 25,323 for study inclusion and randomized those people into one of the main study arms (n = 21,752) or to one of the 2 ancillary treatment arms (n = 3571",100.0
1760,pmid:25811824,Setting,The study took place in 3 large health maintenance organizations.,The study took place in 3 large health maintenance organizations.,100.0
1760,pmid:25811824,Organisation,"UC participants had access to the full range of usual services, including each region’s normal education and care management outreach efforts to encourage statin and ACEI/ARB use.","UC participants had access to the full range of usual services, including each region’s normal education and care management outreach efforts to encourage statin and ACEI/ARB use.",100.0
1760,pmid:25811824,Flexibility (delivery),"IVR participants received automated phone calls when they were due or overdue for a refill. IVR+ participants received these phone calls, plus personalized reminder letters, live outreach calls, EMR-based feedback to their primary care providers, and additional mailed materials.","IVR participants received automated phone calls when they were due or overdue for a refill. IVR+ participants received these phone calls, plus personalized reminder letters, live outreach calls, EMR-based feedback to their primary care providers, and additional mailed materials.",100.0
1760,pmid:25811824,Flexibility (adherence),"We used a modified version of the Proportion of Days Covered (PDC), defined from pharmacy dispensing records, for our primary measure."," used a modified version of the Proportion of Days Covered (PDC),16 defined from pharmacy dispensing records, for our primary measure",98.49624060150376
1760,pmid:25811824,Follow-up,Mean duration of follow-up was 9.6 months and did not vary by treatment arm.,Mean duration of follow-up was 9.6 months and did not vary by treatment arm,100.0
1760,pmid:25811824,Primary outcome,The primary outcome was medication adherence; blood pressure and lipid levels were secondary outcomes.,The primary outcome was medication adherence; blood pressure and lipid levels were secondary outcomes.,100.0
1760,pmid:25811824,Primary analysis,We used an intention-to-treat analysis to compare primary and secondary outcomes between intervention and UC participants.,We used an intention-to-treat analysis to compare primary and secondary outcomes between intervention and UC participants.,100.0
1688,10.1136/annrheumdis-2013-203843,Eligibility,"Biologic-naive patients with active RA and an inadequate response to MTX were randomised to 125 mg abatacept weekly or 40 mg adalimumab bi-weekly, both with a stable dose of MTX.","Biologic-naive patients with active RA and an inadequate response to MTX were randomised to 125 mg abatacept weekly or 40 mg adalimumab bi-weekly, both with a stable dose of MTX.",100.0
1688,10.1136/annrheumdis-2013-203843,Eligibility,"Patients met the 1987 American Rheumatism Association (ARA) criteria for RA, had active disease for ≤5 years despite MTX therapy and were naive to biologic therapy.","Patients met the 1987 American Rheumatism Association (ARA) criteria for RA, had active disease for ≤5 years despite MTX therapy and were naive to biologic therapy.",100.0
1688,10.1136/annrheumdis-2013-203843,Eligibility,"Of 646 patients randomised, 79.2% abatacept and 74.7% adalimumab patients completed year 2.","Of 646 patients randomised, 79.2% abatacept and 74.7% adalimumab patients completed year 2.",100.0
1688,10.1136/annrheumdis-2013-203843,Eligibility,"AMPLE is a 2-year, phase IIIB, multinational, prospective, randomised study comparing subcutaneous abatacept and adalimumab on stable background MTX in patients naive to bDMARDs.","AMPLE is a 2-year, phase IIIB, multinational, prospective, randomised study comparing subcutaneous abatacept and adalimumab on stable background MTX in patients naive to bDMARDs",100.0
1688,10.1136/annrheumdis-2013-203843,Eligibility,"Clinical assessors were blinded to patient treatment and assessed patients’ joints, disease activity and defined adverse event (AE) causality.","Clinical assessors were blinded to patient treatment and assessed patients’ joints, disease activity and defined adverse event (AE) causality.",100.0
1688,10.1136/annrheumdis-2013-203843,Eligibility,Double-blinding of the study drugs was not feasible due to the logistic barrier of masking Humira; patients were not blinded with regard to their study drug.,Double-blinding of the study drugs was not feasible due to the logistic barrier of masking Humira; patients were not blinded with regard to their study drug.,100.0
1688,10.1136/annrheumdis-2013-203843,Eligibility,No adjustment within 56 days of Day 729 was allowed.,No adjustment within 56 days of Day 729 was allowed.,100.0
1688,10.1136/annrheumdis-2013-203843,Eligibility,"Efficacy and safety outcomes were evaluated at days 1, 15, 29 and every 4 weeks thereafter during year 1, and every 3 months during year 2.","Efficacy and safety outcomes were evaluated at days 1, 15, 29 and every 4 weeks thereafter during year 1, and every 3 months during year 2.",100.0
1688,10.1136/annrheumdis-2013-203843,Eligibility,"The primary endpoint was at 1 year but the blinded study continued for 2 years to provide controlled, comparative assessment of long term safety, efficacy and radiographic outcomes.","The primary endpoint was at 1 year but the blinded study continued for 2 years to provide controlled, comparative assessment of long term safety, efficacy and radiographic outcomes.",100.0
1688,10.1136/annrheumdis-2013-203843,Eligibility,All efficacy analyses were assessed using the intent-to-treat (ITT) populations; all safety analyses were assessed using the as-treated population.,All efficacy analyses were assessed using the intent-to-treat (ITT) populations; all safety analyses were assessed using the as-treated population.,100.0
670,10.1016/j.jbmt.2013.04.001,Eligibility,"Participants were clients seen in the multiple sclerosis clinics at Sutherland-Chan School, in which the study was conducted. Clients were provided with information about the clinic by the local chapter of the Multiple Sclerosis Society, and self selected on that basis.","Participants were clients seen in the multiple sclerosis clinics at Sutherland-Chan School, in which the study was conducted. Clients were provided with information about the clinic by the local chapter of the Multiple Sclerosis Society, and self selected on that basis.",100.0
670,10.1016/j.jbmt.2013.04.001,Eligibility,"Of the fifteen study participants, all had previously received a diagnosis of multiple sclerosis.","Of the fifteen study participants, all had previously received a diagnosis of multiple sclerosis.",100.0
670,10.1016/j.jbmt.2013.04.001,Eligibility,"The clients presented to the clinic with a variety of impairments, including some specifically related to the disease process and others that were primarily musculoskeletal in origin.","The clients presented to the clinic with a variety of impairments, including some specifically related to the disease process and others that were primarily musculoskeletal in origin.",100.0
670,10.1016/j.jbmt.2013.04.001,Recruitment,"Clients attending the clinic were interviewed, and their case histories recorded. The research project was explained, and written informed consent was obtained.","Clients attending the clinic were interviewed, and their case histories recorded. The research project was explained, and written informed consent was obtained.",100.0
670,10.1016/j.jbmt.2013.04.001,Recruitment,"The inclusion criterion for the study was a diagnosis of multiple sclerosis, and therefore the spectrum of clinical presentations was broad, as would be expected in this client population.","The inclusion criterion for the study was a diagnosis of multiple sclerosis, and therefore the spectrum of clinical presentations was broad, as would be expected in this client population.",100.0
670,10.1016/j.jbmt.2013.04.001,Setting,"Participants were clients seen in the multiple sclerosis clinics at Sutherland-Chan School, in which the study was conducted.","Participants were clients seen in the multiple sclerosis clinics at Sutherland-Chan School, in which the study was conducted.",100.0
670,10.1016/j.jbmt.2013.04.001,Organisation,The treatment plans were approved by the clinical teacher in charge.,l treatment plans were approved by the clinical teacher in charge. ,95.52238805970148
670,10.1016/j.jbmt.2013.04.001,Organisation,"The teacher also monitored treatment delivery, which involved the application of a variety of techniques appropriate to the client's needs.","The teacher also monitored treatment delivery, which involved the application of a variety of techniques appropriate to the client's needs.",100.0
670,10.1016/j.jbmt.2013.04.001,Flexibility (delivery),"Massage therapy is aligned with the wellness paradigm of health and health care, which speaks to a holistic client centered approach to treatment.","y is aligned with the wellness paradigm of health and health care (Alexander, 2006; Yates, 2004), which speaks to a holistic client centered appr",78.62068965517241
670,10.1016/j.jbmt.2013.04.001,Flexibility (delivery),"Accordingly, if the current research was to conform to the requirements of model fit/ecological validity, it was incumbent on the therapists to construct individualized treatment plans recognizing the importance of the client's physical, psychological and emotional needs."," the current research was to conform to the requirements of model fit/ecological validity (Menard, 2003; Mason et al., 2002), it was incumbent on the therapists to construct individualized treatment plans recognizing the importance of the client's physical, psychological",87.08487084870849
670,10.1016/j.jbmt.2013.04.001,Follow-up,"Self-Efficacy scores were obtained before the first treatment, mid-treatment series, after the last treatment in the series, four weeks after the final treatment and again eight weeks after the final treatment had been received.","Self-Efficacy scores were obtained before the first treatment, mid-treatment series, after the last treatment in the series, four weeks after the final treatment and again eight weeks after the final treatment had been received.",100.0
670,10.1016/j.jbmt.2013.04.001,Primary outcome,"Self-Efficacy [SE] was the outcome for the study, measured using the Multiple Sclerosis Self-Efficacy survey [MSSE].","Self-Efficacy [SE] was the outcome for the study, measured using the Multiple Sclerosis Self-Efficacy survey [MSSE].",100.0
670,10.1016/j.jbmt.2013.04.001,Primary outcome,"The MSSE survey was originally developed and validated by Schwartz et al. (1996), based on the work of Lorig et al. (1989), who created a similar tool for use with people suffering from arthritis.","The MSSE survey was originally developed and validated by Schwartz et al. (1996), based on the work of Lorig et al. (1989), who created a similar tool for use with people suffering from arthritis.",100.0
670,10.1016/j.jbmt.2013.04.001,Primary analysis,"The data were analyzed on an intention to treat basis, with a focus on the differences between mean MSSE values of the control and intervention groups.","The data were analyzed on an intention to treat basis, with a focus on the differences between mean MSSE values of the control and intervention groups.",100.0
1230,10.2106/jbjs.m.01542,Eligibility,"Exclusion criteria included inflammatory arthritis, osteoporosis, Paget disease, corticosteroid use in the last twelve months, acute femoral neck fracture, previous surgery on the involved side, active infection, malignant tumor within the last five years, and other factors that might affect weight-bearing or rehabilitation.","Exclusion criteria included inflammatory arthritis, osteoporosis, Paget disease, corticosteroid use in the last twelve months, acute femoral neck fracture, previous surgery on the involved side, active infection, malignant tumor within the last five years, and other factors that might affect weight-bearing or rehabilitation.",100.0
1230,10.2106/jbjs.m.01542,Eligibility,Patients for whom the appropriate size and offset of implant were not available were also excluded.,Patients for whom the appropriate size and offset of implant were not available were also excluded.,100.0
1230,10.2106/jbjs.m.01542,Recruitment,Subjects between fifty and seventy years of age who presented for primary total hip arthroplasty for noninflammatory arthritis at a single regional orthopaedic center were eligible for enrollment into the study.,Subjects between fifty and seventy years of age who presented for primary total hip arthroplasty for noninflammatory arthritis at a single regional orthopaedic center were eligible for enrollment into the study.,100.0
1230,10.2106/jbjs.m.01542,Setting,"All patients underwent a primary total hip arthroplasty with an SR71 or Stability femoral stem, a 28-mm cobalt-chromium Articul/eze femoral head, and an all-polyethylene cemented Elite Plus Long Posterior Wall acetabular cup (all products produced by DePuy International, Leeds, U.K.).","All patients underwent a primary total hip arthroplasty with an SR71 or Stability femoral stem, a 28-mm cobalt-chromium Articul/eze femoral head, and an all-polyethylene cemented Elite Plus Long Posterior Wall acetabular cup (all products produced by DePuy International, Leeds, U.K.).",100.0
1230,10.2106/jbjs.m.01542,Organisation,The operations were performed by the senior author (D.E.B.) in one center using the posterior approach with the patient in the lateral decubitus position.,The operations were performed by the senior author (D.E.B.) in one center using the posterior approach with the patient in the lateral decubitus position.,100.0
1230,10.2106/jbjs.m.01542,Flexibility (delivery),"The surgical approach, prophylactic measures against infection and thromboembolism, and postoperative rehabilitation varied among surgeons and institutions.","The surgical approach, prophylactic measures against infection and thromboembolism, and postoperative rehabilitation varied among surgeons and institutions",100.0
1230,10.2106/jbjs.m.01542,Follow-up,"Patients were followed for up to ten years with repeated assessments of bone mineral density, radiographs, Harris hip scores (HHS), and visual analog scale (VAS) pain scores.","Patients were followed for up to ten years with repeated assessments of bone mineral density, radiographs, Harris hip scores (HHS), and visual analog scale (VAS) pain scores.",100.0
1230,10.2106/jbjs.m.01542,Primary outcome,"The primary outcome measure was bone mineral density as measured by dual x-ray absorptiometry (DXA) scan (Lunar Prodigy, GE Medical Systems, Diegem, Belgium).","The primary outcome measure was bone mineral density as measured by dual x-ray absorptiometry (DXA) scan (Lunar Prodigy, GE Medical Systems, Diegem, Belgium).",100.0
1230,10.2106/jbjs.m.01542,Primary analysis,There were no differences in patient demographics or outcome measures at baseline between the two implant groups.,There were no differences in patient demographics or outcome measures at baseline between the two implant groups,100.0
1683,10.1136/annrheumdis-2011-201247,Eligibility,"Eligible patients were 18 years or older with a diagnosis of RA based on the 1987 ACR classification criteria,4 with a disease duration from diagnosis of less than 1 year.","Eligible patients were 18 years or older with a diagnosis of RA based on the 1987 ACR classification criteria,4 with a disease duration from diagnosis of less than 1 year.",100.0
1683,10.1136/annrheumdis-2011-201247,Eligibility,"Patients must have met the following five criteria: (1) disease activity score based on 28 joints (DAS28) and C-reactive protein (CRP) greater than 3.2; (2) tender joint count based on 68 joints (TJC68) of 8 or greater; (3) swollen joint count based on 66 joints (SJC66) of 6 or greater; (4) erythrocyte sedimentation rate of 28 mm/h or greater or CRP of 1.5 mg/dl or greater and (5) either rheumatoid factor (RF) positive, anticyclic citrullinated peptide positive, or more than one erosion on the hands or feet by x-ray.","Patients must have met the following five criteria: (1) disease activity score based on 28 joints (DAS28) and C-reactive protein (CRP) greater than 3.2; (2) tender joint count based on 68 joints (TJC68) of 8 or greater; (3) swollen joint count based on 66 joints (SJC66) of 6 or greater; (4) erythrocyte sedimentation rate of 28 mm/h or greater or CRP of 1.5 mg/dl or greater and (5) either rheumatoid factor (RF) positive, anticyclic citrullinated peptide positive, or more than one erosion on the hands or feet by x-ray.",100.0
1683,10.1136/annrheumdis-2011-201247,Eligibility,"Patients who had received previous methotrexate, more than two synthetic DMARD, anti-TNF therapy, or any other biological DMARD were excluded, as were those receiving intra-articular or parenteral corticosteroids in the 4 weeks preceding screening.","Patients who had received previous methotrexate, more than two synthetic DMARD, anti-TNF therapy, or any other biological DMARD were excluded, as were those receiving intra-articular or parenteral corticosteroids in the 4 weeks preceding screening.",100.0
1683,10.1136/annrheumdis-2011-201247,Recruitment,"OPTIMA (NCT00420927) was conducted at 161 centres in North and South America, Europe, Africa, New Zealand and Australia from December 2006 to July 2010.","OPTIMA (NCT00420927) was conducted at 161 centres in North and South America, Europe, Africa, New Zealand and Australia from December 2006 to July 2010.",100.0
1683,10.1136/annrheumdis-2011-201247,Setting,"OPTIMA (NCT00420927) was conducted at 161 centres in North and South America, Europe, Africa, New Zealand and Australia from December 2006 to July 2010.","OPTIMA (NCT00420927) was conducted at 161 centres in North and South America, Europe, Africa, New Zealand and Australia from December 2006 to July 2010.",100.0
1683,10.1136/annrheumdis-2011-201247,Organisation,The frequencies of total AE and serious AE were similar between the ADA+MTX and PBO+MTX groups.,The frequencies of total AE and serious AE were similar between the ADA+MTX and PBO+MTX groups,100.0
1683,10.1136/annrheumdis-2011-201247,Flexibility (delivery),Treatment modifications were to be made in a subsequent study period based on the achievement of DAS28(CRP) <3.2 at weeks 22 and 26.,Treatment modifications were to be made in a subsequent study period based on the achievement of DAS28(CRP) <3.2 at weeks 22 and 26.,100.0
1683,10.1136/annrheumdis-2011-201247,Flexibility (adherence),The overall frequency of adverse events was comparable between groups.,The overall frequency of adverse events was comparable between groups.,100.0
1683,10.1136/annrheumdis-2011-201247,Follow-up,"Clinical assessments during period 1 were performed at baseline and weeks 2, 4, 8, 12, 22 and 26.","Clinical assessments during period 1 were performed at baseline and weeks 2, 4, 8, 12, 22 and 26.",100.0
1683,10.1136/annrheumdis-2011-201247,Primary outcome,The primary endpoint of the study was a composite of DAS28(CRP) less than 3.2 at week 78 and no radiographic progression from baseline to week 78 in the van der Heijde modified total Sharp score (ΔmTSS ≤0.5).,The primary endpoint of the study was a composite of DAS28(CRP) less than 3.2 at week 78 and no radiographic progression from baseline to week 78 in the van der Heijde modified total Sharp score (ΔmTSS ≤0.5).,100.0
1683,10.1136/annrheumdis-2011-201247,Primary analysis,The intent-to-treat population included all randomly assigned patients who received at least one dose of study drug.,The intent-to-treat population included all randomly assigned patients who received at least one dose of study drug.,100.0
697,10.1002/pmrj.12377,Eligibility,"Inclusion criteria were the following: diagnosis of MS made by a neurologist, able to walk 10 meters with or without an aid within 2 minutes, no relapse of their MS in the past 4 weeks, and no other neurological or orthopedic condition that would affect their function."," Inclusion criteria were the following: diagnosis of MS made by a neurologist, able to walk 10 meters with or without an aid within 2 minutes, no relapse of their MS in the past 4 weeks, and no other neurological or orthopedic condition that would affect their functio",100.0
697,10.1002/pmrj.12377,Eligibility,"Eligible participants were excluded from the study if they were already engaged in a formal exercise program lasting >30 minutes twice per week, experienced an exacerbation within the past 4 weeks, had their MS immunomodulation medications altered in the previous 4 weeks or during the trial period, or declined to be randomly allocated."," Eligible participants were excluded from the study if they were already engaged in a formal exercise program lasting >30 minutes twice per week, experienced an exacerbation within the past 4 weeks, had their MS immunomodulation medications altered in the previous 4 weeks or during the trial period, or declined to be randomly allocate",100.0
697,10.1002/pmrj.12377,Recruitment,Community dwelling people with MS were recruited through the Multiple Sclerosis Society of New South Wales and South Australia.,Community dwelling people with MS were recruited through the Multiple Sclerosis Society of New South Wales and South Australia.,100.0
697,10.1002/pmrj.12377,Recruitment,"Participants were assessed at two points at baseline (8 weeks apart) to establish stability of presentation, at the end of an 8-week training period and at 8-week follow-up."," Participants were assessed at two points at baseline (8 weeks apart) to establish stability of presentation, at the end of an 8-week training period and at 8-week follow-u",100.0
697,10.1002/pmrj.12377,Setting,The group program was conducted at a local community center and included four to six participants per class.,The group program was conducted at a local community center and included four to six participants per class.,100.0
697,10.1002/pmrj.12377,Setting,"Home exercise participants were provided with one center-based physiotherapist-led session at the commencement of the intervention period for training, and telephone support by a physiotherapist to discuss their program every 2 weeks.","
Home exercise participants were provided with one center-based physiotherapist-led session at the commencement of the intervention period for training, and telephone support by a physiotherapist to discuss their program every 2 week",100.0
697,10.1002/pmrj.12377,Organisation,"The group program was conducted at a local community center and included four to six participants per class. Groups were led by a physiotherapist employed by the Multiple Sclerosis Society who received training to ensure a standard approach to intervention, intensity, and progression.","The group program was conducted at a local community center and included four to six participants per class. Groups were led by a physiotherapist employed by the Multiple Sclerosis Society who received training to ensure a standard approach to intervention, intensity, and progression.",100.0
697,10.1002/pmrj.12377,Organisation,"Home exercise participants were provided with one center-based physiotherapist-led session at the commencement of the intervention period for training, and telephone support by a physiotherapist to discuss their program every 2 weeks.","
Home exercise participants were provided with one center-based physiotherapist-led session at the commencement of the intervention period for training, and telephone support by a physiotherapist to discuss their program every 2 week",100.0
697,10.1002/pmrj.12377,Flexibility (delivery),"The exercise program for both groups included two, 60-minute sessions per week, held at least 2 days apart for 8 weeks.","
The exercise program for both groups included two, 60-minute sessions per week, held at least 2 days apart for 8 week",100.0
697,10.1002/pmrj.12377,Flexibility (delivery),"Exercises were aimed at improving gait speed, endurance, and balance. They were individualized, specific, progressed in load, and performed at a moderate to high intensity.","Exercises were aimed at improving gait speed, endurance, and balance. They were individualized, specific, progressed in load, and performed at a moderate to high intensity.",100.0
697,10.1002/pmrj.12377,Follow-up,"Participants attended a local community center to complete all assessments at pre-intervention (week 0), post-intervention (week 8), and at follow-up (week 16).","Participants attended a local community center to complete all assessments at pre-intervention (week 0), post-intervention (week 8), and at follow-up (week 16).",100.0
697,10.1002/pmrj.12377,Follow-up,"Participants were assessed at two points at baseline (8 weeks apart) to establish stability of presentation, at the end of an 8-week training period and at 8-week follow-up."," Participants were assessed at two points at baseline (8 weeks apart) to establish stability of presentation, at the end of an 8-week training period and at 8-week follow-u",100.0
697,10.1002/pmrj.12377,Primary outcome,The primary outcome was gait speed (10-meter walk test).,The primary outcome was gait speed (10-meter walk test).,100.0
697,10.1002/pmrj.12377,Primary outcome,"Results revealed no group effect, time effect, or group x time interactions for the primary outcome measure of gait speed.","
Results revealed no group effect, time effect, or group x time interactions for the primary outcome measure of gait spee",100.0
697,10.1002/pmrj.12377,Primary analysis,Data were analyzed according to the intention-to-treat principle.,Data were analyzed according to the intention-to-treat principle.,100.0
697,10.1002/pmrj.12377,Primary analysis,Differences between groups at baseline were analyzed using analysis of variance (ANOVA) for continuous data and Mann-Whitney U tests for interval data.,Differences between groups at baseline were analyzed using analysis of variance (ANOVA) for continuous data and Mann-Whitney U tests for interval data.,100.0
1445,10.1016/j.athoracsur.2011.07.083,Eligibility,This study compared sympathicotomy over the second (R2) vs third (R3) costal head relative to these variables in patients with massive palmar hyperhidrosis.,This study compared sympathicotomy over the second (R2) vs third (R3) costal head relative to these variables in patients with massive palmar hyperhidrosis.,100.0
1445,10.1016/j.athoracsur.2011.07.083,Eligibility,A total of 121 consecutive patients with the classic manifestations of disabling palmoplantar hyperhidrosis [6] were prospectively randomized to R2 or R3 sympathicotomy.,A total of 121 consecutive patients with the classic manifestations of disabling palmoplantar hyperhidrosis [6] were prospectively randomized to R2 or R3 sympathicotomy.,100.0
1445,10.1016/j.athoracsur.2011.07.083,Eligibility,The 6 patients whose hyperhidrosis was not cured were significantly younger than those patients whose sympathicotomies were completely curative (19.7 ± 2.5 vs 26.4 ± 8.0 years; p = 0.04).,The 6 patients whose hyperhidrosis was not cured were significantly younger than those patients whose sympathicotomies were completely curative (19.7 ± 2.5 vs 26.4 ± 8.0 years; p = 0.04).,100.0
1445,10.1016/j.athoracsur.2011.07.083,Recruitment,"These 121 patients had bilateral procedures (ie, 2 sympathicotomies per patient) for a total of 142 procedures (122 R2 and 120 R3).","These 121 patients had bilateral procedures (ie, 2 sympathicotomies per patient) for a total of 142 procedures (122 R2 and 120 R3).",100.0
1445,10.1016/j.athoracsur.2011.07.083,Recruitment,The patients frequently were treated with medical management before they sought consultation for surgical consideration.,The patients frequently were treated with medical management before they sought consultation for surgical consideration.,100.0
1445,10.1016/j.athoracsur.2011.07.083,Recruitment,"For those patients without prior medical treatments and whose insurance carriers so required, we initiated topical aluminum chloride hexahydrate 20% (Drysol, Person & Covey, Glendale, CA) or 6.25% (Xerac AC, Person & Covey) in anhydrous ethyl alcohol, oral glycopyrrolate (Robinul, Shionogi USA Inc, Florham Park, NJ) at progressively increased dosages, or iontophoresis with the Drionic device (General Medical, Los Angeles, CA), despite the realization that these medical treatments would likely fail.","For those patients without prior medical treatments and whose insurance carriers so required, we initiated topical aluminum chloride hexahydrate 20% (Drysol, Person & Covey, Glendale, CA) or 6.25% (Xerac AC, Person & Covey) in anhydrous ethyl alcohol, oral glycopyrrolate (Robinul, Shionogi USA Inc, Florham Park, NJ) at progressively increased dosages, or iontophoresis with the Drionic device (General Medical, Los Angeles, CA), despite the realization that these medical treatments would likely fail.",100.0
1445,10.1016/j.athoracsur.2011.07.083,Setting,All operations were done as outpatient procedures.,All operations were done as outpatient procedures,100.0
1445,10.1016/j.athoracsur.2011.07.083,Organisation,The surgical techniques were as previously described [10].,The surgical techniques were as previously described [10].,100.0
1445,10.1016/j.athoracsur.2011.07.083,Organisation,The study design and subject informed consent form were reviewed and approved by the Doctors Surgery Center Institutional Review Board.,The study design and subject informed consent form were reviewed and approved by the Doctors Surgery Center Institutional Review Board.,100.0
1445,10.1016/j.athoracsur.2011.07.083,Flexibility (delivery),The surgical techniques were as previously described [10].,The surgical techniques were as previously described [10].,100.0
1445,10.1016/j.athoracsur.2011.07.083,Flexibility (adherence),The patients frequently were treated with medical management before they sought consultation for surgical consideration.,The patients frequently were treated with medical management before they sought consultation for surgical consideration.,100.0
1445,10.1016/j.athoracsur.2011.07.083,Follow-up,Patients were questioned at 6 months and after 1 year by phone or mail survey.,Patients were questioned at 6 months and after 1 year by phone or mail survey.,100.0
1445,10.1016/j.athoracsur.2011.07.083,Primary outcome,This study compared sympathicotomy over the second (R2) vs third (R3) costal head relative to these variables in patients with massive palmar hyperhidrosis.,This study compared sympathicotomy over the second (R2) vs third (R3) costal head relative to these variables in patients with massive palmar hyperhidrosis.,100.0
1445,10.1016/j.athoracsur.2011.07.083,Primary analysis,The Wilcoxon rank sum test was used for differences in continuous variables between sympathicotomy groups.,The Wilcoxon rank sum test was used for differences in continuous variables between sympathicotomy groups.,100.0
1445,10.1016/j.athoracsur.2011.07.083,Primary analysis,The Pearson χ2 test with Yates continuity correction was used for differences in dichotomous outcomes.,The Pearson χ2 test with Yates continuity correction was used for differences in dichotomous outcomes.,100.0
1445,10.1016/j.athoracsur.2011.07.083,Primary analysis,Logistic regression analysis was used to analyze multiple category exposures.,Logistic regression analysis was used to analyze multiple category exposures.,100.0
1691,10.1136/ard.2007.080002,Eligibility,"Eligible patients met the American College of Rheumatology (ACR) criteria for RA, were at least 18 years of age, had RA for at least 1 year, and had an inadequate response to MTX, as demonstrated by ongoing active disease (at randomisation ⩾10 swollen joints, ⩾12 tender joints, and C-reactive protein (CRP) levels ⩾1 mg/dl using a high sensitivity assay (upper limit of the normal range, 0.5)).","ligible patients met the American College of Rheumatology (ACR) criteria for RA, were at least 18 years of age, had RA for at least 1 year,4 and had an inadequate response to MTX, as demonstrated by ongoing active disease (at randomisation ⩾10 swollen joints, ⩾12 tender joints, and C-reactive protein (CRP) levels ⩾1 mg/dl using a high sensitivity assay (upper limit of the normal range, 0.5",99.74489795918367
1691,10.1136/ard.2007.080002,Recruitment,"The study utilised a double-blind, randomised, placebo-controlled design for the first 6 months to validate efficacy responses, and the study duration allowed for the opportunity to directly compare the safety profile of the active biologic treatment groups over 1 year.","The study utilised a double-blind, randomised, placebo-controlled design for the first 6 months to validate efficacy responses, and the study duration allowed for the opportunity to directly compare the safety profile of the active biologic treatment groups over 1 year.",100.0
1691,10.1136/ard.2007.080002,Setting,"The ATTEST (for “Abatacept or infliximab vs placebo, a Trial for Tolerability, Efficacy and Safety in Treating rheumatoid arthritis”) trial was designed to obtain data on the magnitude of the treatment effect in RA of abatacept or infliximab (an established inhibitor of TNF for RA) vs placebo, and to obtain relative efficacy and safety data on these two biological treatments in a single study.","The ATTEST (for “Abatacept or infliximab vs placebo, a Trial for Tolerability, Efficacy and Safety in Treating rheumatoid arthritis”) trial was designed to obtain data on the magnitude of the treatment effect in RA of abatacept or infliximab (an established inhibitor of TNF for RA) vs placebo, and to obtain relative efficacy and safety data on these two biological treatments in a single study.",100.0
1691,10.1136/ard.2007.080002,Organisation,"Overall, abatacept had a relatively more acceptable safety and tolerability profile, with fewer SAEs, serious infections, acute infusional events and discontinuations due to AEs than the infliximab group.","Overall, abatacept had a relatively more acceptable safety and tolerability profile, with fewer SAEs, serious infections, acute infusional events and discontinuations due to AEs than the infliximab group.",100.0
1691,10.1136/ard.2007.080002,Flexibility (delivery),"Abatacept was dosed according to weight: patients weighing less than 60 kg, 60–100 kg, or more than 100 kg received 500 mg, 750 mg, or 1000 mg of abatacept, respectively. Infliximab was dosed at 3 mg/kg for all patients.","Abatacept was dosed according to weight: patients weighing less than 60 kg, 60–100 kg, or more than 100 kg received 500 mg, 750 mg, or 1000 mg of abatacept, respectively. Infliximab was dosed at 3 mg/kg for all patients.",100.0
1691,10.1136/ard.2007.080002,Flexibility (adherence),"Between days 198–365, when the protocol permitted adjustments to background medications, 12.8% and 17.6% of abatacept and infliximab-treated patients, respectively, added a DMARD, or increased their dose of MTX/corticosteroids from baseline.","Between days 198–365, when the protocol permitted adjustments to background medications, 12.8% and 17.6% of abatacept and infliximab-treated patients, respectively, added a DMARD, or increased their dose of MTX/corticosteroids from baseline.",100.0
1691,10.1136/ard.2007.080002,Follow-up,"During the entire 12-month, double-blind period (days 1–365), SAEs, related SAEs, and discontinuations due to SAEs were lower with abatacept than infliximab.","During the entire 12-month, double-blind period (days 1–365), SAEs, related SAEs, and discontinuations due to SAEs were lower with abatacept than infliximab",100.0
1691,10.1136/ard.2007.080002,Primary outcome,"The primary endpoint was to evaluate a reduction in disease activity, measured by Disease Activity Score 28 (based on erythrocyte sedimentation rate levels; DAS28 (ESR)) with abatacept vs placebo at 6 months.","The primary endpoint was to evaluate a reduction in disease activity, measured by Disease Activity Score 28 (based on erythrocyte sedimentation rate levels; DAS28 (ESR)) with abatacept vs placebo at 6 months.",100.0
1691,10.1136/ard.2007.080002,Primary analysis,All patients who received at least one dose of study medication were assessed for efficacy and safety (intent-to-treat population).,All patients who received at least one dose of study medication were assessed for efficacy and safety (intent-to-treat population).,100.0
655,10.1016/j.arbres.2020.03.034,Eligibility,"Patient selection criteria were having a diagnosis of moderate-to-severe COPD (a Body mass index, Airflow obstruction, dyspnoea and Exercise capacity [BODE] index score of 3–7) according to international guidelines and having been clinically stable for the previous 4 weeks.","atient selection criteria were having a diagnosis of moderate-to-severe COPD (a Body mass index, Airflow obstruction, dyspnoea and Exercise capacity [BODE] index score of 3–7) according to international guidelines9 and having been clinically stable for the previous 4 weeks",99.63369963369964
655,10.1016/j.arbres.2020.03.034,Eligibility,"Recruited patients (recruitment visit, −1) attended an initial 8-week outpatient-based PR programme conducted in each hospital rehabilitation department.","Recruited patients (recruitment visit, −1) attended an initial 8-week outpatient-based PR programme conducted in each hospital rehabilitation department.",100.0
655,10.1016/j.arbres.2020.03.034,Eligibility,All patients gave written informed consent.,All patients gave written informed consent.,100.0
655,10.1016/j.arbres.2020.03.034,Eligibility,A multicentre open-label pragmatic parallel-group randomized clinical trial involving 13 hospitals.,a multicentre open-label pragmatic parallel-group randomized clinical trial involving 13 hospitals,100.0
655,10.1016/j.arbres.2020.03.034,Eligibility,Patients in the IG were asked to continue at home with a similar training schedule to that completed in the hospital.,Patients in the IG were asked to continue at home with a similar training schedule to that completed in the hospital.,100.0
655,10.1016/j.arbres.2020.03.034,Eligibility,Patients in the IG were asked to continue at home with a similar training schedule to that completed in the hospital.,Patients in the IG were asked to continue at home with a similar training schedule to that completed in the hospital.,100.0
655,10.1016/j.arbres.2020.03.034,Eligibility,Patients were considered non-adherent if they did not attend any 2 follow-up appointments and there was no clear clinical justification for not attending.,Patients were considered non-adherent if they did not attend any 2 follow-up appointments and there was no clear clinical justification for not attending.,100.0
655,10.1016/j.arbres.2020.03.034,Eligibility,"After the randomization visit, follow-up appointments were arranged for both groups at 3, 9 and 12 months.","After the randomization visit, follow-up appointments were arranged for both groups at 3, 9 and 12 months.",100.0
655,10.1016/j.arbres.2020.03.034,Eligibility,The analysis of covariance showed non-significant improvements in 6-min walk distance [19.9 m (95% CI −4.1/+43.8)] and Chronic Respiratory Disease Questionnaire – Emotion score [0.4 points (0–0.8)] in the IG.,The analysis of covariance showed non-significant improvements in 6-min walk distance [19.9 m (95% CI −4.1/+43.8)] and Chronic Respiratory Disease Questionnaire – Emotion score [0.4 points (0–0.8)] in the IG.,100.0
655,10.1016/j.arbres.2020.03.034,Eligibility,All available data from the randomized patients were used in the mixed models.,All available data from the randomized patients were used in the mixed models.,100.0
1395,10.1227/neu.0b013e3182284aca,Eligibility,Inclusion and exclusion criteria (Table 2) had to be met before enrollment.,Inclusion and exclusion criteria (Table 2) had to be met before enrollment.,100.0
1395,10.1227/neu.0b013e3182284aca,Eligibility,The key inclusion criteria consisted of a scheduled elective cranial procedure requiring a dural incision and an expectation of a class I/clean wound.,The key inclusion criteria consisted of a scheduled elective cranial procedure requiring a dural incision and an expectation of a class I/clean wound.,100.0
1395,10.1227/neu.0b013e3182284aca,Eligibility,Acute cranial trauma and malignant cranial tumor procedures were exclusions from this study.,Acute cranial trauma and malignant cranial tumor procedures were exclusions from this study.,100.0
1395,10.1227/neu.0b013e3182284aca,Recruitment,"A multicenter, prospective, randomized, controlled clinical trial, registered with ClinicalTrials.gov (NCT00859508), was performed under a U.S. Food and Drug Administration–approved investigational device exemption protocol.","A multicenter, prospective, randomized, controlled clinical trial, registered with ClinicalTrials.gov (NCT00859508), was performed under a U.S. Food and Drug Administration–approved investigational device exemption protocol.",100.0
1395,10.1227/neu.0b013e3182284aca,Recruitment,"The decision to use Onlay versus Substitute was made intraoperatively by the surgeon, based on the size of the defect and type of repair needed to achieve a watertight seal.","The decision to use Onlay versus Substitute was made intraoperatively by the surgeon, based on the size of the defect and type of repair needed to achieve a watertight seal.",100.0
1395,10.1227/neu.0b013e3182284aca,Setting,"A multicenter, prospective, randomized, controlled clinical trial, registered with ClinicalTrials.gov (NCT00859508), was performed under a U.S. Food and Drug Administration–approved investigational device exemption protocol.","A multicenter, prospective, randomized, controlled clinical trial, registered with ClinicalTrials.gov (NCT00859508), was performed under a U.S. Food and Drug Administration–approved investigational device exemption protocol.",100.0
1395,10.1227/neu.0b013e3182284aca,Organisation,"The control group consisted of dural replacement devices that had been previously cleared for marketing by the U.S. Food and Drug Administration via a premarket notification, or 510(k), and thus determined to be substantially equivalent.","The control group consisted of dural replacement devices that had been previously cleared for marketing by the U.S. Food and Drug Administration via a premarket notification, or 510(k), and thus determined to be substantially equivalent.",100.0
1395,10.1227/neu.0b013e3182284aca,Flexibility (delivery),A duraplasty is performed using BSC cut to the desired shape.,A duraplasty is performed using BSC cut to the desired shape.,100.0
1395,10.1227/neu.0b013e3182284aca,Flexibility (delivery),"To achieve close reapproximation, use the smallest appropriate diameter sutures with a tapered needle, not larger than the diameter of the suture.","To achieve close reapproximation, use the smallest appropriate diameter sutures with a tapered needle, not larger than the diameter of the suture.",100.0
1395,10.1227/neu.0b013e3182284aca,Follow-up,"Patients were evaluated preoperatively, immediately postoperatively (within 10 days), and at 1, 3, and 6 months.","Patients were evaluated preoperatively, immediately postoperatively (within 10 days), and at 1, 3, and 6 months.",100.0
1395,10.1227/neu.0b013e3182284aca,Primary outcome,The primary endpoint for this study was the absence of pseudomeningocele and extracerebral fluid collection confirmed by radiographic evaluation and the absence of CSF fistula (drainage from wound) at the 6-month postoperative visit.,The primary endpoint for this study was the absence of pseudomeningocele and extracerebral fluid collection confirmed by radiographic evaluation and the absence of CSF fistula (drainage from wound) at the 6-month postoperative visit.,100.0
1395,10.1227/neu.0b013e3182284aca,Primary analysis,"The primary hypothesis of this study is that, with regard to key clinical outcomes, the BSC device is not inferior to dural replacements cleared for marketing by the U.S. Food and Drug Administration.","The primary hypothesis of this study is that, with regard to key clinical outcomes, the BSC device is not inferior to dural replacements cleared for marketing by the U.S. Food and Drug Administration.",100.0
1186,10.1016/j.arthro.2010.02.020,Eligibility,"Inclusion criteria were patients who had frozen shoulder without abnormal findings on radiography, magnetic resonance imaging, or ultrasound. All patients complained of shoulder pain and stiffness without a response to conservative treatment for at least 6 months.","Inclusion criteria were patients who had frozen shoulder without abnormal findings on radiography, magnetic resonance imaging, or ultrasound. All patients complained of shoulder pain and stiffness without a response to conservative treatment for at least 6 months.",100.0
1186,10.1016/j.arthro.2010.02.020,Eligibility,"Exclusion criteria were patients with shoulder stiffness after humeral head fracture with internal fixation, shoulder surgery, locked anterior or posterior dislocation, severe glenohumeral osteoarthritis, or tumor.","Exclusion criteria were patients with shoulder stiffness after humeral head fracture with internal fixation, shoulder surgery, locked anterior or posterior dislocation, severe glenohumeral osteoarthritis, or tumor.",100.0
1186,10.1016/j.arthro.2010.02.020,Recruitment,This prospective study enrolled 74 consecutive patients who underwent arthroscopic capsular release for frozen shoulder at our institution between May 2000 and October 2006.,This prospective study enrolled 74 consecutive patients who underwent arthroscopic capsular release for frozen shoulder at our institution between May 2000 and October 2006.,100.0
1186,10.1016/j.arthro.2010.02.020,Setting,This prospective study enrolled 74 consecutive patients who underwent arthroscopic capsular release for frozen shoulder at our institution between May 2000 and October 2006.,This prospective study enrolled 74 consecutive patients who underwent arthroscopic capsular release for frozen shoulder at our institution between May 2000 and October 2006.,100.0
1186,10.1016/j.arthro.2010.02.020,Organisation,"All patients were given a consent form, with approval from the medical ethical committee of our hospital, before their surgery and underwent the same rehabilitation protocol after their surgery.","All patients were given a consent form, with approval from the medical ethical committee of our hospital, before their surgery and underwent the same rehabilitation protocol after their surgery.",100.0
1186,10.1016/j.arthro.2010.02.020,Flexibility (delivery),"The patients were immobilized with a sling for 4 weeks, unless they performed physical exercise. All patients began passive ROM exercises with the therapist the day after surgery. They were instructed to begin performing the full range of passive ER0 early as possible.","the patients were immobilized with a sling for 4 weeks, unless they performed physical exercise. All patients began passive ROM exercises with the therapist the day after surgery. They were instructed to begin performing the full range of passive ER0 early as possible",100.0
1186,10.1016/j.arthro.2010.02.020,Follow-up,"Except for 4 patients lost to follow-up, follow-up was obtained in 70 patients, including 41 patients in group 1 and 29 patients in group 2, with a mean of 28 months (range, 26 to 32 months).","Except for 4 patients lost to follow-up, follow-up was obtained in 70 patients, including 41 patients in group 1 and 29 patients in group 2, with a mean of 28 months (range, 26 to 32 months).",100.0
1186,10.1016/j.arthro.2010.02.020,Primary outcome,The aims of our study were to assess effects of the extent of capsular release and to define the benefit of additional release of the inferior glenohumeral ligament (IGHL) from inferior to posterior in frozen shoulder.,The aims of our study were to assess effects of the extent of capsular release and to define the benefit of additional release of the inferior glenohumeral ligament (IGHL) from inferior to posterior in frozen shoulder.,100.0
1186,10.1016/j.arthro.2010.02.020,Primary analysis,"Data were analyzed with SPSS software (SPSS, Chicago, IL). Statistical analysis was performed by use of the Wilcoxon signed-rank test for preoperative and postoperative motion and Constant scores, as well as to compare the 2 cohorts at corresponding time points.","Data were analyzed with SPSS software (SPSS, Chicago, IL). Statistical analysis was performed by use of the Wilcoxon signed-rank test for preoperative and postoperative motion and Constant scores, as well as to compare the 2 cohorts at corresponding time points.",100.0
729,10.1093/ageing/afu033,Eligibility,"Eligibility criteria included living at home and receiving case manager care, being housebound or attending day centres in Bradford, UK.","Eligibility criteria included living at home and receiving case manager care, being housebound or attending day centres in Bradford, UK.",100.0
729,10.1093/ageing/afu033,Eligibility,"People were excluded if they were unable to stand and walk independently; currently participating in an alternative exercise programme; registered blind. Those who had poorly controlled angina; had another household member already in the trial; had severe dementia or were receiving palliative care, were also excluded.","People were excluded if they were unable to stand and walk independently; currently participating in an alternative exercise programme; registered blind. Those who had poorly controlled angina; had another household member already in the trial; had severe dementia or were receiving palliative care, were also excluded.",100.0
729,10.1093/ageing/afu033,Recruitment,"Verbal assent was first sought by the member of the health or social services team coordinating individual care. Potential participants identified from GP registers were contacted by letter from the practice and responses were mailed directly to the study team. Those expressing an interest were visited at home by trained clinical researchers who undertook detailed screening, explained the study in full to eligible candidates and provided written information leaflets. Informed consent was obtained prior to baseline assessment.","Verbal assent was first sought by the member of the health or social services team coordinating individual care. Potential participants identified from GP registers were contacted by letter from the practice and responses were mailed directly to the study team. Those expressing an interest were visited at home by trained clinical researchers who undertook detailed screening, explained the study in full to eligible candidates and provided written information leaflets. Informed consent was obtained prior to baseline assessment.",100.0
729,10.1093/ageing/afu033,Setting,"The trial was conducted in Bradford, UK."," attending day centres in Bradford, UK.",66.66666666666667
729,10.1093/ageing/afu033,Setting,The intervention was delivered by Bradford Teaching Hospitals NHS Foundation Trust community physiotherapists.,the intervention was delivered by Bradford Teaching Hospitals NHS Foundation Trust community physiotherapists,100.0
729,10.1093/ageing/afu033,Organisation,"The control group continued to receive usual care from the primary healthcare team and, other than baseline and follow-up assessments, had no contact with the research team.","The control group continued to receive usual care from the primary healthcare team and, other than baseline and follow-up assessments, had no contact with the research team.",100.0
729,10.1093/ageing/afu033,Organisation,"Physiotherapists receive intervention training in a 2-h workshop. At the beginning of the intervention, participants are requested to perform five repetitions of each exercise in the routine. This progresses to 10 and then 15 repetitions as performance improves. The exercise routine takes <15 min to complete, and participants are requested to complete the routine three times a day on 5 days of the week.","Physiotherapists receive intervention training in a 2-h workshop. At the beginning of the intervention, participants are requested to perform five repetitions of each exercise in the routine. This progresses to 10 and then 15 repetitions as performance improves. The exercise routine takes <15 min to complete, and participants are requested to complete the routine three times a day on 5 days of the week.",100.0
729,10.1093/ageing/afu033,Flexibility (delivery),Participants receive weekly support from physiotherapists through five face-to-face home visits and seven telephone calls.,Participants receive weekly support from physiotherapists through five face-to-face home visits and seven telephone calls.,100.0
729,10.1093/ageing/afu033,Flexibility (delivery),"If participants are coping well with the exercises they are encouraged to progress within the programme. Progression is by increasing repetitions, introducing new exercises or advancing to the next level of the HOPE programme.","If participants are coping well with the exercises they are encouraged to progress within the programme. Progression is by increasing repetitions, introducing new exercises or advancing to the next level of the HOPE programme.",100.0
729,10.1093/ageing/afu033,Flexibility (adherence),"Adherence diaries were returned by 27 of the 28 participants (96%) who completed the 12-week intervention. Of the adherence diaries returned, the mean diary completion was 64%, the mean total adherence was 46% and the mean partial or total adherence was 67%.","Adherence diaries were returned by 27 of the 28 participants (96%) who completed the 12-week intervention. Of the adherence diaries returned, the mean diary completion was 64%, the mean total adherence was 46% and the mean partial or total adherence was 67%.",100.0
729,10.1093/ageing/afu033,Follow-up,Follow-up information is therefore available for 70 participants (83% of those randomised; 40 intervention participants and 30 control participants).,Follow-up information is therefore available for 70 participants (83% of those randomised; 40 intervention participants and 30 control participants,100.0
729,10.1093/ageing/afu033,Follow-up,All outcomes were collected at baseline and at 14 weeks post-randomisation.,All outcomes were collected at baseline and at 14 weeks post-randomisation.,100.0
729,10.1093/ageing/afu033,Primary outcome,"The primary outcome was mobility, measured using the timed-up-and-go test (TUGT).",". Primary outcome was mobility, measured using the timed-up-and-go test (TUGT).",96.20253164556962
729,10.1093/ageing/afu033,Primary outcome,"There was a non-significant trend towards a clinically important improved outcome in the intervention group (mean adjusted between-group difference in the TUGT 28.6 s, 95% CI −8.5, 65.9 s).","There was a non-significant trend towards a clinically important improved outcome in the intervention group (mean adjusted between-group difference in the TUGT 28.6 s, 95% CI −8.5, 65.9 s).",100.0
729,10.1093/ageing/afu033,Primary analysis,Missing data were addressed by listwise exclusion.,Missing data were addressed by listwise exclusion,100.0
729,10.1093/ageing/afu033,Primary analysis,The final intention-to-treat analysis included all randomised participants for whom the follow-up assessment of the primary outcome measure was available.,The final intention-to-treat analysis included all randomised participants for whom the follow-up assessment of the primary outcome measure was available.,100.0
1254,10.2106/jbjs.h.00769,Eligibility,"There were forty-nine women and five men with a mean age (and standard deviation) of 69.7 ± 6.43 years (range, fifty-five to eighty-five years) at the time of surgery.","There were forty-nine women and five men with a mean age (and standard deviation) of 69.7 ± 6.43 years (range, fifty-five to eighty-five years) at the time of surgery.",100.0
1254,10.2106/jbjs.h.00769,Eligibility,"There was no substantial difference between the two cohorts in terms of preoperative conditions, including the extent of disease, pain, functional disability, deformity, range of motion, bone loss, and/or prior surgical treatments.","There was no substantial difference between the two cohorts in terms of preoperative conditions, including the extent of disease, pain, functional disability, deformity, range of motion, bone loss, and/or prior surgical treatments.",100.0
1254,10.2106/jbjs.h.00769,Recruitment,"From October to December 2004, the senior author (Y.-H.K.) performed fifty-nine consecutive primary bilateral total knee arthroplasties in fifty-nine patients.","From October to December 2004, the senior author (Y.-H.K.) performed fifty-nine consecutive primary bilateral total knee arthroplasties in fifty-nine patients.",100.0
1254,10.2106/jbjs.h.00769,Setting,"The study was registered in the ClinicalTrials.gov Protocol Registration System (trial number, NCT00837447).","The study was registered in the ClinicalTrials.gov Protocol Registration System (trial number, NCT00837447).",100.0
1254,10.2106/jbjs.h.00769,Organisation,All patients underwent a single-stage bilateral (sequential) total knee arthroplasty under one anesthetic.,All patients underwent a single-stage bilateral (sequential) total knee arthroplasty under one anesthetic.,100.0
1254,10.2106/jbjs.h.00769,Flexibility (delivery),The knee was placed in a continuous-passive-motion machine after the splint was removed. All patients began walking with crutches or a walker and started active and passive range-of-motion exercises on the second day after the operation.,The knee was placed in a continuous-passive-motion machine after the splint was removed. All patients began walking with crutches or a walker and started active and passive range-of-motion exercises on the second day after the operation.,100.0
1254,10.2106/jbjs.h.00769,Follow-up,"Clinical and radiographic evaluations were done at three months after the operation, at one year, and then yearly thereafter.","Clinical and radiographic evaluations were done at three months after the operation, at one year, and then yearly thereafter.",100.0
1254,10.2106/jbjs.h.00769,Primary outcome,"The mean postoperative Knee Society and Hospital for Special Surgery knee scores were 93.7 and 89 points, respectively, for the knees with a standard posterior cruciate-retaining prosthesis, and they were 93.9 and 90 points, respectively, for the knees with a high-flexion posterior cruciate-retaining prosthesis.","The mean postoperative Knee Society and Hospital for Special Surgery knee scores were 93.7 and 89 points, respectively, for the knees with a standard posterior cruciate-retaining prosthesis, and they were 93.9 and 90 points, respectively, for the knees with a high-flexion posterior cruciate-retaining prosthesis.",100.0
1254,10.2106/jbjs.h.00769,Primary analysis,"The changes in the Knee Society, the Hospital for Special Surgery, and the WOMAC scores were evaluated with use of the Student paired t test and the Pearson nonparametric chi-square test.","The changes in the Knee Society, the Hospital for Special Surgery, and the WOMAC scores were evaluated with use of the Student paired t test and the Pearson nonparametric chi-square test.",100.0
657,10.1093/ptj/pzz017,Eligibility,Eighty people with Expanded Disability Status scores of 1 to 6.5 participated in this trial.,Eighty people with Expanded Disability Status scores of 1 to 6.5 participated in this trial.,100.0
657,10.1093/ptj/pzz017,Eligibility,"The inclusion criteria were as follows: (1) diagnosed with MS in accordance with the McDonald criteria27; (2) registered at the MS outpatient clinic; (3) living in 1 of 6 selected municipalities; (4) aged 18 years or older; (5) capable of providing signed written informed consent; and (6) EDSS score between 1 and 6.5 (1 = minor disability, 6.5 = able to walk 20 m with or without a walking aid).","The inclusion criteria were as follows: (1) diagnosed with MS in accordance with the McDonald criteria27; (2) registered at the MS outpatient clinic; (3) living in 1 of 6 selected municipalities; (4) aged 18 years or older; (5) capable of providing signed written informed consent; and (6) EDSS score between 1 and 6.5 (1 = minor disability, 6.5 =  able to walk 20 m with or without a walking ai",99.74683544303798
657,10.1093/ptj/pzz017,Recruitment,"In August 2015, 1 of the MS nurses at the Department of Neurology, Nordland Hospital Trust in Bodø, Norway, sent out invitation letters with a consent form to 160 persons with MS who were registered at the MS outpatient clinic, had EDSS scores of 0 to 7, and lived in 1 of the 6 municipalities included in the study.","In August 2015, 1 of the MS nurses at the Department of Neurology, Nordland Hospital Trust in Bodø, Norway, sent out invitation letters with a consent form to 160 persons with MS who were registered at the MS outpatient clinic, had EDSS scores of 0 to 7, and lived in 1 of the 6 municipalities included in the study.",100.0
657,10.1093/ptj/pzz017,Recruitment,Ninety-three persons returned signed written informed consent.,Ninety-three persons returned signed written informed consent.,100.0
657,10.1093/ptj/pzz017,Setting,The GroupCoreDIST intervention was conducted by 6 physical therapists in 6 municipalities in Norway.,The GroupCoreDIST intervention was conducted by 6 physical therapists in 6 municipalities in Norway.,100.0
657,10.1093/ptj/pzz017,Setting,Standard care included the usual care for individuals with MS in the same municipalities.,Standard care included the usual care for individuals with MS in the same municipalities.,100.0
657,10.1093/ptj/pzz017,Flexibility (delivery),The exercises were individualized to ensure that key impairments contributing to reduced balance and trunk control were addressed in each individual.,The exercises were individualized to ensure that key impairments contributing to reduced balance and trunk control were addressed in each individual.,100.0
657,10.1093/ptj/pzz017,Flexibility (delivery),"The physical therapists individualized the exercises by tailoring them according to each individual's symptoms, disability level, and general well-being, and they intensified the exercises by increasing number of repetitions, level of difficulty, and/or by adding motor-cognitive dual tasks as movement quality improved.","The physical therapists individualized the exercises by tailoring them according to each individual's symptoms, disability level, and general well-being, and they intensified the exercises by increasing number of repetitions, level of difficulty, and/or by adding motor-cognitive dual tasks as movement quality improved.",100.0
657,10.1093/ptj/pzz017,Follow-up,"Assessments were conducted at baseline and at weeks 7, 18, and 30.","Assessments were conducted at baseline and at weeks 7, 18, and 30.",100.0
657,10.1093/ptj/pzz017,Follow-up,"The results demonstrated that 6 weeks of GroupCoreDIST compared with standard care led to significant between-group effects in favor of the intervention group on balance and trunk control at 7, 18, and 30 weeks.","The results demonstrated that 6 weeks of GroupCoreDIST compared with standard care led to significant between-group effects in favor of the intervention group on balance and trunk control at 7, 18, and 30 weeks.",100.0
657,10.1093/ptj/pzz017,Primary outcome,"The TIS-NV, which requires quality of movement and cooperation between body segments in dynamic sitting balance,29 detected a short-term improvement of 19% in the intervention group, which we consider a clinically meaningful change.","The TIS-NV, which requires quality of movement and cooperation between body segments in dynamic sitting balance,29 detected a short-term improvement of 19% in the intervention group, which we consider a clinically meaningful change.",100.0
657,10.1093/ptj/pzz017,Primary outcome,The Mini-BESTest demonstrated an overall statistically significant difference between groups (P < .001).,The Mini-BESTest demonstrated an overall statistically significant difference between groups (P < .001).,100.0
657,10.1093/ptj/pzz017,Primary analysis,The results of the mixed-model analysis are shown in Table 3.,The results of the mixed-model analysis are shown in Table 3.,100.0
657,10.1093/ptj/pzz017,Primary analysis,The estimated marginal means were used to make plots illustrating the effects of the intervention over time.,The estimated marginal means were used to make plots illustrating the effects of the intervention over time.,100.0
1489,10.1016/s0140-6736(19)31281-4,Eligibility,"We used a combined expertise-based and equipoise-based approach, in which patients with isolated osteoarthritis of the medial compartment of the knee and who satisfied general requirements for a medial PKR were randomly assigned (1:1) to receive PKR or TKR by surgeons who were either expert in and willing to perform both surgeries or by a surgeon with particular expertise in the allocated procedure.","We used a combined expertise-based and equipoise-based approach, in which patients with isolated osteoarthritis of the medial compartment of the knee and who satisfied general requirements for a medial PKR were randomly assigned (1:1) to receive PKR or TKR by surgeons who were either expert in and willing to perform both surgeries or by a surgeon with particular expertise in the allocated procedure.",100.0
1489,10.1016/s0140-6736(19)31281-4,Eligibility,We recruited patients from 27 sites across the UK (and 68 surgeons at these sites). Potential participants were identified in outpatient and pre-assessment clinics by participating surgeons.,We recruited patients from 27 sites across the UK (and 68 surgeons at these sites). Potential participants were identified in outpatient and pre-assessment clinics by participating surgeons.,100.0
1489,10.1016/s0140-6736(19)31281-4,Eligibility,"Our multicentre, pragmatic randomised controlled trial was done at 27 UK sites.","Our multicentre, pragmatic randomised controlled trial was done at 27 UK sites.",100.0
1489,10.1016/s0140-6736(19)31281-4,Eligibility,The types of implants used in the study reflected current practice.,The types of implants used in the study reflected current practice,100.0
1489,10.1016/s0140-6736(19)31281-4,Eligibility,"Our trial compared the TKR procedure versus the PKR procedure rather than a specific brand of TKR implant versus a specific brand of PKR implant. As such, surgeons were free to use the implant of their own choice, or that of their institution.","Our trial compared the TKR procedure versus the PKR procedure rather than a specific brand of TKR implant versus a specific brand of PKR implant. As such, surgeons were free to use the implant of their own choice, or that of their institution.",100.0
1489,10.1016/s0140-6736(19)31281-4,Eligibility,"Some non-compliance with allocation (ie, conversion from PKR to TKR from operative findings) was anticipated and clinically understandable but a complier-average causal effects analysis that we used to assess the potential effects of non-compliance on outcomes did not find any issue.","Some non-compliance with allocation (ie, conversion from PKR to TKR from operative findings) was anticipated and clinically understandable but a complier-average causal effects analysis that we used to assess the potential effects of non-compliance on outcomes did not find any issue.",100.0
1489,10.1016/s0140-6736(19)31281-4,Eligibility,"Patients attended a clinic for an American Knee Society Score assessment and a complication review 2 months, 1 year, and 5 years after their operation. All other outcomes were collected with postal questionnaires at 2 months after the operation and 1 year after randomisation and, thereafter, annually (until 5 years after randomisation).","Patients attended a clinic for an American Knee Society Score assessment and a complication review 2 months, 1 year, and 5 years after their operation. All other outcomes were collected with postal questionnaires at 2 months after the operation and 1 year after randomisation and, thereafter, annually (until 5 years after randomisation).",100.0
1489,10.1016/s0140-6736(19)31281-4,Eligibility,The primary outcome measure was the OKS 5 years after randomisation in all patients assigned to groups.,The primary outcome measure was the OKS 5 years after randomisation in all patients assigned to groups.,100.0
1489,10.1016/s0140-6736(19)31281-4,Eligibility,The statistical analysis was primarily on an intention-to-treat basis and used all available participant data.,the statistical analysis was primarily on an intention-to-treat basis and used all available participant data,100.0
1381,10.3171/2015.7.jns151026,Eligibility,"After giving informed consent, 57 patients with movement disorders—mostly PD but also dystonia and tremor—underwent bilateral DBS implantation in the same operation in the globus pallidus internus (GPi), the subthalamic nucleus (STN), or the thalamic ventralis intermedius nucleus (Vim), according to the medical indication.","After giving informed consent, 57 patients with movement disorders—mostly PD but also dystonia and tremor—underwent bilateral DBS implantation in the same operation in the globus pallidus internus (GPi), the subthalamic nucleus (STN), or the thalamic ventralis intermedius nucleus (Vim), according to the medical indication.",100.0
1381,10.3171/2015.7.jns151026,Eligibility,"Considering that most of the subjects were PD patients receiving bilateral implants in the STN (34 patients), we compared the clinical effects of STN stimulation between the groups undergoing each of the techniques by using the Unified Parkinson's Disease Rating Scale Part III (UPDRS-III), Hoehn and Yahr Scale, and levodopa-equivalent dose before and 1 year after DBS.","Considering that most of the subjects were PD patients receiving bilateral implants in the STN (34 patients), we compared the clinical effects of STN stimulation between the groups undergoing each of the techniques by using the Unified Parkinson's Disease Rating Scale Part III (UPDRS-III), Hoehn and Yahr Scale, and levodopa-equivalent dose before and 1 year after DBS.",100.0
1381,10.3171/2015.7.jns151026,Recruitment,"After giving informed consent, 57 patients with movement disorders—mostly PD but also dystonia and tremor—underwent bilateral DBS implantation in the same operation in the globus pallidus internus (GPi), the subthalamic nucleus (STN), or the thalamic ventralis intermedius nucleus (Vim), according to the medical indication.","After giving informed consent, 57 patients with movement disorders—mostly PD but also dystonia and tremor—underwent bilateral DBS implantation in the same operation in the globus pallidus internus (GPi), the subthalamic nucleus (STN), or the thalamic ventralis intermedius nucleus (Vim), according to the medical indication.",100.0
1381,10.3171/2015.7.jns151026,Setting,The procedures were performed within the period from June 2012 to December 2014.,The procedures were performed within the period from June 2012 to December 2014.,100.0
1381,10.3171/2015.7.jns151026,Setting,Our local ethics committee approved this study.,Our local ethics committee approved this study.,100.0
1381,10.3171/2015.7.jns151026,Organisation,The simultaneous bilateral implant procedures were 38.5% faster than the conventional bilateral approach.,the simultaneous bilateral implant procedures were 38.5% faster than the conventional bilateral approach,100.0
1381,10.3171/2015.7.jns151026,Organisation,"Overall, shorter procedures are more comfortable for the patient, who is therefore more likely to cooperate with the clinical examination, possibly improving the information provided to the surgical team during the process of decision making regarding electrode positioning.","Overall, shorter procedures are more comfortable for the patient, who is therefore more likely to cooperate with the clinical examination, possibly improving the information provided to the surgical team during the process of decision making regarding electrode positioning.",100.0
1381,10.3171/2015.7.jns151026,Flexibility (delivery),"The proposed simultaneous approach resulted in the superimposition of a significant portion of the procedure, mainly regarding microelectrode recording, DBS electrode positioning, and the fluoroscopy check.","The proposed simultaneous approach resulted in the superimposition of a significant portion of the procedure, mainly regarding microelectrode recording, DBS electrode positioning, and the fluoroscopy check",100.0
1381,10.3171/2015.7.jns151026,Flexibility (delivery),"The simultaneous approach also allowed microelectrode recording to be performed simultaneously, with at least 2 channels on each side and recording channels converging to the same 5-channel amplifier.","The simultaneous approach also allowed microelectrode recording to be performed simultaneously, with at least 2 channels on each side and recording channels converging to the same 5-channel amplifier.",100.0
1381,10.3171/2015.7.jns151026,Flexibility (adherence),"The simultaneous approach also allowed microelectrode recording to be performed simultaneously, with at least 2 channels on each side and recording channels converging to the same 5-channel amplifier.","The simultaneous approach also allowed microelectrode recording to be performed simultaneously, with at least 2 channels on each side and recording channels converging to the same 5-channel amplifier.",100.0
1381,10.3171/2015.7.jns151026,Follow-up,Only 20 patients who had completed 1-year follow-up were considered for this analysis.,Only 20 patients who had completed 1-year follow-up were considered for this analysis.,100.0
1381,10.3171/2015.7.jns151026,Primary outcome,"Regarding clinical outcomes in the PD patients who underwent subthalamic nucleus DBS implantation, comparing the preoperative off-medication condition with the off-medication/on-stimulation condition 1 year after the surgery in both procedure groups, there was a mean 47.8% ± 9.5% improvement in the Unified Parkinson's Disease Rating Scale Part III (UPDRS-III) score in the simultaneous group, while the sequential group experienced 47.5% ± 15.8% improvement (p = 0.96).","Regarding clinical outcomes in the PD patients who underwent subthalamic nucleus DBS implantation, comparing the preoperative off-medication condition with the off-medication/on-stimulation condition 1 year after the surgery in both procedure groups, there was a mean 47.8% ± 9.5% improvement in the Unified Parkinson's Disease Rating Scale Part III (UPDRS-III) score in the simultaneous group, while the sequential group experienced 47.5% ± 15.8% improvement (p = 0.96).",100.0
1381,10.3171/2015.7.jns151026,Primary analysis,"The 2 groups of PD patients who underwent STN implantation were considered objectively homogeneous in the preoperative state, and no significant differences in the clinical outcomes were observed between the groups 1 year after the DBS implant.","The 2 groups of PD patients who underwent STN implantation were considered objectively homogeneous in the preoperative state, and no significant differences in the clinical outcomes were observed between the groups 1 year after the DBS implant.",100.0
